



HILTON ANTWERP

FEBRUARY 21-23 2018





Personalized nursing *service @ home* *



Nex2You



Stiv@Home

For more information please send mail to info@bayer.be

* Nex2You: for patients receiving Sorafenib.
Stiv@Home: for patients receiving Regorafenib.

Dear Colleagues,

It is our pleasure to welcome you to the **XXXth Edition of the Belgian Week of GastroEnterology**.

Enclosed you will find the complete program of this meeting. Many high quality abstracts, illustrating the high level of both basic and clinical research in Belgium, have been selected for oral presentation during the scientific meeting.

Besides these scientific sections that constitute the backbone of the congress for many years, the **BWGE 2018** offers several other attractive sessions and activities!

The program has been substantially changed compared to previous editions, as we start already on Wednesday afternoon with several exciting sessions, relevant for both clinicians and scientists. This is also the aim of the whole Belgian Week: bringing together clinicians and researchers in a stimulating meeting.

The scientific steering committee decided not to organise a Plenary Session of **the Belgian Week of GastroEnterology**, so the best abstracts of the several societies and research groups remain an integral part of the dedicated sessions. Several state-of-the-art lectures by national and international key-opinion leaders figure throughout the program and numerous satellites, organized by some of our sponsors, further add to the number of interesting lectures to attend.

Posters will be permanently displayed on interactive screens in the exhibition hall. Some of the best posters will be discussed during lunchtime in a separate area in the exhibition hall. We encourage you to attend these sessions and support our young researchers.

The ultrasound course (with a first session on Wednesday and a second session on Thursday) is intended for both unexperienced and experienced sonographers, with possibility to train on healthy volunteers as well as on sophisticated phantoms mimicking human disease and real time imaging.

The Belgian Society of Gastrointestinal Endoscopy organises for the second time a live endoscopy session, scheduled on Friday afternoon.

The Young Belgian Association for the Study of the Liver again participates with an ethics and economy-accredited scientific session on Wednesday.

During the **Interactive Case Report Session** on Wednesday afternoon and on Thursday morning, interesting and rare cases will be discussed and commented on.

Brand new this year is the **session on Proctology** on Friday morning!

On Wednesday evening, after the scientific sessions, we welcome you at our get-together reception in the exhibition hall, an excellent occasion to meet friends and colleagues!

Do not forget to join as for the **celebration of this XXXth edition on Thursday evening at the MAS, Museum** on the roof top, with a splendid view of the harbor and the city.

We hope you will enjoy a stimulating scientific meeting!



Welcome	3
General Information	6
Steering Committee	7
Invited Lectures	8 – 9
Satellite Symposia	10 – 11

Wednesday February 21

Belgian Inflammatory Bowel Diseases Research and Development (BIRD)	13 – 14
E-Posters BIRD	16 – 19
E-Posters Helicobacter	19
Young BASL	20
Belgian Pancreatic Club (BPC)	22
Case Reports Session 1	23
Ultrasound Course Session 1	24
Welcome Reception	25

Thursday February 22

Belgian Association for the Study of the Liver (BASL)	27 – 33
Congress Overview	34 – 35
Belgian Association for the Study of the Liver (BASL)	36 – 37
E-Posters BASL	38 – 39
Belgian Network on Gastrointestinal Regulatory Mechanisms (GIREM)	40 – 43
Case Reports Session 2	44
E-Posters with Short Talk: Basic	45
Belgian Inflammatory Bowel Diseases Research and Development (BIRD)	46 – 48

Thursday February 22

E-Posters Belgian Society of Gastrointestinal Endoscopy (BSGIE)	49
Belgian Society of Gastrointestinal Endoscopy (BSGIE)	50 – 52
Ultrasound Course Session 2	53
XXX th Anniversary Dinner & Party	54

Friday February 23

BSGIE Live Transmission Session	55
BWGE 2018 Awards Ceremony	56
Belgian Group of Proctology	57
Belgian Group for Digestive Oncology (BGDO)	58 – 62
E-Posters Belgian Group for Digestive Oncology (BGDO)	62 – 63
Working Group of Digestive Pathology	64 – 65
Belgian Society for Paediatric Gastroenterology, Hepatology and Nutrition (BeSPGHAN)	66 – 67
E-Posters BeSPGHAN	67
E-Posters with Short Talk: Clinical	68 – 69
BWGE 2019 Save the Date	70
BINASTORIA Meeting	71

ACCREDITATION

CME credits will be provided by online submission to the registered delegates who have attended the sessions. The file from the online accreditation registrations will be sent to the **INAMI/ RIZIV** end of March 2018.

LANGUAGES

Dutch, French and English. English for abstracts, slides and announcements. As proposed at the Steering Committee of 1995, Belgian authors may present their original papers in their mother tongue.

BWGE XXXTH ANNIVERSARY EVENT AND DINNER MAS Museum, Antwerpen THURSDAY FEBRUARY 22TH, 2018

VENUE

HILTON ANTWERPEN

Groenplaats, 32 - 2000 Antwerpen

Tel: +32 3 204 12 12

Website : www.hilton.com/hotel/antwerp

EVENT COORDINATOR / SCIENTIFIC SECRETARY

DME-EVENTS SPRL / BVBA - ANNE-FRANCE DE MEYER

57 av. G. Demeylaan - 1160 Bruxelles / Brussel

Tel. +32 477.27.00.45

E-mail: anne.france.de.meyer@dme-events.eu

SCIENTIFIC COORDINATORS

SVEN FRANQCQUE

ISABELLE COLLE

SEVEN SOCIETIES

PHILIP CAENEPEEL, MARC PEETERS

VVGE: Vlaamse Vereniging voor GastroEnterologie.

CATHERINE VAN KEMSEKE, GONTRAN VERSET

SRBGE: Société Royale Belge de GastroEnterologie.

DANIEL BLERO, DANNY DE LOOZE,

HUBERT PIESSEVAUX

BSGIE: Belgian Society of Gastrointestinal Endoscopy.

ARNAUD DE ROOVER, JAN LERUT

RBSS: Royal Belgian Society of Surgery.

LIEVEN VAN HOE, CRISTINA DRAGEAN

BSR: Belgian Society of Radiology, Section of Abdominal Imaging.

CHRISTOPHE MORENO, ANJA GEERTS

BASL: Belgian Association for the Study of the Liver.

IVAN BORBATH, MARC PEETERS

BGDO: Belgian Group of Digestive Oncology.

RESEARCH GROUP

INGE DEPOORTERE

GIREM: Belgian Network on Gastrointestinal Regulatory Mechanisms.

ANNE HOORENS, ANN DRIESSEN

WGDP: Working Group of Digestive Pathology.

ILSE HOFFMAN, FRANÇOISE SMETS

BESPGHAN: Belgian Society for Paediatric Gastroenterology Hepatology and Nutrition.

ANDRÉ VAN GOSSUM

SBNC: Société Belge de Nutrition Clinique.

DIRK YSEBAERT

VVKVM: Vlaamse Vereniging voor Klinische Voeding en Metabolism.

JEAN-FRANÇOIS RAHIER

PIETER HINDRYCKX

BIRD: Belgian IBD Research and Development.

MYRIAM DELHAYE

BPC: Belgian Pancreatic Club.

PATRICK BONTEMS, FAZIA MANA

BHPSG: Belgian Microbiota and Helicobacter Study Group.

OLIVIER DETRY, JACQUES PIRENNE

BLIC: Belgian Liver Intestine Committee.

ROLAND HUSTINX, CHRISTOPHE DEROOSE

BELNUC: Belgian Society of Nuclear Medicine.

LEO VAN GRUNSVEN

Basic research groups.

YVES-PAUL VANDEWYNCKEL

Young BASL.

ANNELEEN VAN HOOTEGEM

Young VVGE.

JEOFFREY SCHOUTEN

Ultrasound Course.

INVITED LECTURES

Wednesday February 21

BIRD

- Massimo Fantini / Rome, Italy : Why animal models of IBD are still relevant.
- Wiebe Vanhove / Leuven : Benefits and limitations of pre-clinical in vitro and ex vivo work.
- Gerhard Rogler / Zurich, Switzerland : The exposome in IBD: what needs to be done?

BPC

- M. Delhaye, P. Demetter / ULB Erasme
Diagnosis of pancreatic cystic lesions.
The view of the clinician – The view of the pathologist
- J. van Hoof / Amsterdam, The Netherlands
Management of autoimmune pancreatitis in 2018.

Young BASL

- Renee Tolba / Aachen, Germany : Animal models in liver disease: from law to practice.
- Johan Neyts / KULeuven Antiviral therapy: From bench to bedside.

Thursday February 22

BASL

- Vincent Leroy / Grenoble, France: Diagnostic approach of cholestasis: when it is neither PBC nor PSC.
- Valerio Lucidi / ULB, Brussels: Surgical management of early HCC: Resection is the first option
- Jacques Pirenne / KULeuven: Surgical management of early HCC: Liver transplantation is the first option

GIREM

- A. BEYDER / Rochester, USA: The touchy business of GI mucosal mechanosensitivity.
- G. MAZZUOLI-WEBER / Hannover, Germany: Enteric neurons and mechanosensitivity: MEN at work.
- J. FICHNA / Lodz, Poland: Lipids and irritable bowel syndrome – an (un)likely connection.

BIRD

- Charlie Lees / Edinburgh, UK: JAK inhibitors: can they replace biologicals?
- Marc Van Ranst / Leuven: JAK inhibitors: is the increased risk of viral infections a real threat?
- Shomron Ben-Horin / Tel Aviv, Israel: Initiating biological therapies in IBD: Do I have to use other drugs for CD than for UC?

BSGIE

- Marek Bugajski / Warsaw, Poland: ESGE quality indicators for lower GI endoscopy.
- E. Dekker / Amsterdam, The Netherlands: Optical diagnosis: How do I do it?

Friday February 23

BGDO

- Magali Svrcek / Paris, France
 - Marc Van Den Eynde / UCL Bruxelles
 - Anne Demols / ULB Bruxelles
 - Hans Prenen / UZ Leuven
- MSI testing in GI cancer: challenges and pitfalls.
 Highlights of the year: Upper GI cancers
 Highlights of the year: Hepato-Bilio-Pancreatic cancers
 Highlights of the year: Colo-Rectal cancers

DIGESTIVE PATHOLOGY

- M. Rugge / Padova, Italy:
 - G. Cathomas / Liestal, Switzerland:
 - A. Driessen / UZ Antwerpen
 - A. Hoorens / UZ Gent:
- Non-HP gastritis.
 Non-IBD colitis.
 Auto-immune enteropathy.
 Neuroendocrine neoplasms of the GI tract: NET, NEC and MiNEN in the WHO 2017 classification.
- L. Libbrecht / UCL Saint-Luc:
- Disorders of the colon secondary to diagnostic procedures and treatments unrelated to drugs.

PROCTOLOGY

- D. DE LOOZE / UZ Gent:
 - O. RICHEL / Amsterdam, Netherlands:
- Sexually transmitted diseases of the anorectum.
 Manifestations of Human Papilloma Virus infection at the anal canal – anal intraepithelial neoplasia – early detection and prevention.

BESPGHAN

- Els Van de Vijver / UZ Antwerpen
 - Karen Van Hoeve / UZ Leuven
- Diagnostic value of faecal calprotectine.
 Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.
 Human milk oligosaccharides in clinical studies.
- Philippe Alliet / Jessa Ziekenhuis, Hasselt
 - Bruno Hauser / UZ Brussel
- Gastric emptying in children in health and disease: an update for daily clinical practice.
- Isabelle Scheers / UCL St Luc
 - Ruth De Bruyne / UZ Ghent
- Diagnostic and therapeutic challenges in pediatric chronic Pancreatitis.
 Immunological consequences of liver transplantation in children: making or breaking tolerance.

SATELLITE SYMPOSIA

Wednesday 21

**Targeting IL-23/-12 in Crohn's disease:
Experience from across the border.**

Prof. T. KÜHBACHER, Hamburg (Germany)



JANSSEN-CILAG

Thursday 22



**Changing perspectives
in primary biliary cholangitis (PBC)**

Prof. F. NEVENS, UZ Leuven
Prof. C. MORENO, ULB Erasme Brussels



Screening and awareness initiatives in Belgium

Prof. I. COLLE, ASZ Aalst
Dr B. BASTENS, CHC Liège
Prof. J. SCHOUTEN, AZ Nikolaas
Dr. C. VANSTEENKISTE, AZ Maria Middelaes Gent



**PK/PD for guiding therapy with vedolizumab:
Lessons from clinical experience**

Prof. S. BEN-HORIN, Tel-Aviv (Israël)



**Beyond the efficacy of HCV treatments:
What does really matter? A pros and cons debate**

Dr. N. REAU, Chicago (USA)
Dr A. BROWN, London (UK)



Is Nash the next HCV?

Prof. P. MATHURIN, Lille (France)

BMS - Pfizer
Alliance

**Anticoagulation & GE:
Where are we after 5 years of NOAC?**

Prof. P. DEPRez, UCL Saint-Luc Brussels,
Prof. K. JOCHMANS, UZ Brussel

Wednesday 21

**New MOAs /pathways in the IBD World
Pfizer Symposium**
Prof. Charlie Lees (UK)



Friday 23

Optimizing sequential treatment in gastric cancer

Prof. M. VAN DEN EYNDE, UCL Saint-Luc Brussels
Prof. E. VAN CUTSEM, UZ Leuven
Prof J-L. VAN LAETHEM, ULB Erasme, Brussels
Prof. M. PEETERS, UZAntwerpen



Redefining third line therapy in metastatic colorectal cancer

Prof. M. VAN DEN EYNDE, UCL Saint-Luc Brussels
Prof. E. VAN CUTSEM, UZ Leuven
Prof J-L. VAN LAETHEM, ULB Erasme, Brussels
Prof. M. PEETERS, UZAntwerpen



Are we understanding immunotherapy ?

Prof. P. COULIE, UCL Saint-Luc Brussels
Prof. E. VAN CUTSEM, UZ Leuven



Bristol-Myers Squibb Belgium

Janssen-Sponsored Satellite Symposium at the Belgian Week of Gastroenterology (BWGE) - 30th edition, Antwerp, Belgium

Targeting IL-23/-12 in Crohn's disease : experience from across the border

Wednesday 21 February 2018
13h15 - 14h00

Speaker

Prof. Dr. med. habil. Tanja Kühbacher

*Head of the Department of Gastroenterology / Internal Medicine,
Asklepios Westklinikum Rissen, Hamburg*

Moderator

Prof. Dr. Séverine Vermeire,

UZ Leuven

Venue

Hilton Hotel Antwerp
Conference Center, Room "Lijn"

SESSION 1: From the bed back to the bench

CHAIRS: Pieter Hindryckx (Gent), Gianluca Matteoli (Leuven)

13:15 **Satellite Symposium: Janssen-Cilag.**

Invited speaker: Tanja KÜHBACHER / Hamburg, Germany

14:00 **Invited Lecture: Why animal models of IBD are still relevant.**

Massimo Fantini / Rome, Italy

14:25 I01 **Aberrant Muc1 and Muc13 expression in association with Par polarity complex and Vip dysfunction in a colitis T cell transfer model.**

T. BREUGELMANS, H. VAN SPAENDONK, M. HEYLEN, J. DE MAN, B. DE WINTER, A. SMET / UAAntwerpen

14:35 I02 **Transcriptomic profile of inflamed colonic biopsies from newly diagnosed Crohn's disease and ulcerative colitis patients depend on the age at diagnosis.**

S. VERSTOCKT (1), B. VERSTOCKT (1), J. VAN BOUWEL (1), W. MEERT (1), A. CORTES CALABUIG (1), V. BRYNS (1), V. BALLEET (1), E. GLORIEUS (2), M. DE DECKER (3), G. VAN ASSCHE (1), P. HINDRYCKX (2), M. FERRANTE (1), D. LAUKENS (2), F. MANA (3), M. DE VOS (2), S. VERMEIRE (1), I. CLEYNEN (1) / [1] UZ Leuven, [2] UZ Gent, [3] UZ Brussel

14:45 I03 **Baseline ILC1 distribution in blood predicts response to ustekinumab in patients with refractory Crohn's disease.**

B. CREYNS, B. VERSTOCKT, J. CREMER, M. FERRANTE, S. VERMEIRE, J. CEUPPENS, G. VAN ASSCHE, C. BREYNAERT / KULeuven

14:55 I04 **Endoplasmic Reticulum stress in bordering epithelium of Crohn's disease patients with intestinal fibrosis.**

S. HU (1), N. BLÉTARD (2), C. MASSOT (2), N. PIERRE (1), F. QUESADA CALVO (1), G. PAULISSEN (1), G. MAZZUCHELLI (1), N. SMARGIASSO (1), D. BAIWIR (1), E. DE PAUW (1), P. DELVENNE (2), M. MEUWIS (1), E. LOUIS (2) / [1] ULiège, [2] CHU Liège

15:05 **Invited Lecture: Benefits and limitations of pre-clinical in vitro and ex vivo work.**

Wiebe Vanhove / Leuven

15:30 **Coffee Break**

SESSION 2: The forgotten environment in IBD**CHAIRS:** Edouard Louis (Liège), Anneline Cremer (Brussels)**16:00 I 05 Serum proteomic analysis characterizes newly diagnosed Crohn's diseases and ulcerative colitis depending on the age at diagnosis.**

S. VERSTOCKT (1), E. GLORIEUS (2), M. DE DECKER (3), B. VERSTOCKT (4), N. ARDESHIR DAVANI (4), V. BALLETT (1), G. VAN ASSCHE (1), P. HINDRYCKX (2), M. FERRANTE (1), D. LAUKENS (2), F. MANA (3), M. DE VOS (2), S. VERMEIRE (1), I. CLEYNEN (1) / [1] UZ Leuven, [2] UZ Gent, [3] UZ Brussel, [4] KULeuven.

16:10 I 06 Serum proteomic profiling reveals changes in inflammatory profiles with consecutive biological therapies in patients with inflammatory bowel disease.

M. DE BRUYN (1), V. BALLETT (2), S. VERSTOCKT (1), B. VERSTOCKT (1), G. VAN ASSCHE (2), M. FERRANTE (2), K. MACHIELS (1), S. VERMEIRE (2) / [1] KULeuven, [2] UZ Leuven.

16:20 I 07 Protein biomarkers identify subclinical inflammation patterns in first degree relatives of patients with inflammatory bowel disease.

M. VANCAMELBEKE (1), V. BALLETT (1), N. ARDESHIR DAVANI (2), G. VAN ASSCHE (2), M. FERRANTE (2), I. CLEYNEN (2), S. VERMEIRE (2) / [1] UZ Leuven, [2] KULeuven.

16:30 I 08 Decreased leukocyte trafficking may contribute to vedolizumab refractory disease after anti-TNF exposure in patients with ulcerative colitis.

B. VERSTOCKT, S. VERSTOCKT, M. DE BRUYN, K. MACHIELS, H. BLEVI, V. BALLETT, G. VAN ASSCHE, S. VERMEIRE, M. FERRANTE / UZ Leuven

16:40 Invited Lecture: The exposome in IBD: what needs to be done?

Gerhard Rogler / Zurich, Switzerland.

17:00 Satellite symposium Pfizer

Invited speaker: Charlie Lees / UK

17:45 BIRD General Assembly

New MOAs/pathways in the IBD world

Pfizer-Sponsored
Satellite Symposium at the



Satellite Symposium

Wednesday February 21, 2018

Timing: 17:00 – 17:45

30th BWGE -2018

Hilton Hotel Antwerp

Room Lijn

Speaker

Prof. Charlie Lees



- Gastroenterologist Western General Hospital, Edinburgh & senior lecturer at the University of Edinburgh
- Chair educational committee of the European Crohn's & Colitis Organisation
- Chair of the Scottish Society of Gastroenterology IBD Interest Group

117 Immunosuppressive co-treatment with Infliximab and Adalimumab is not superior to anti-TNF monotherapy to prevent treatment failure and treatment discontinuation in ulcerative colitis.

S. VIEUJEAN, E. LOUIS, C. REENAERS / CHU Sart Tilman, Liège

118 Dried Blood Spot Sampling Can Facilitate Therapeutic Drug Monitoring of Vedolizumab Therapy.

S. BIAN (1), L. VANDERSMISSEN (1), S. TOPS (1), E. DREESEN (1), M. FERRANTE (2), S. VERMEIRE (2), A. GILS (1) / [1] KULeuven, [2] UZ Leuven

119 Adaptive dosing during infliximab induction therapy can improve mucosal healing rates in patients with ulcerative colitis.

E. DREESEN (1), R. FAELENS (1), G. VAN ASSCHE (2), M. FERRANTE (2), S. VERMEIRE (2), A. GILS (1), T. BOUILLON (1) / [1] KULeuven, [2] UZ Leuven

120 Reactive dose escalation of infliximab in patients with Crohn's disease in TAILORIX leads to improved outcomes.

E. DREESEN (1), D. LAHARIE (2), G. LAMBRECHT (3), P. BOSSUYT (4), A. BUISSON (5), J. FILIPPI (6), P. VAN HOOTEGEM (7), G. D'HAENS (8), S. VERMEIRE (9), A. GILS (1) / [1] KULeuven, [2] Hospital Haut-Lévêque, Bordeaux, France, [3] Damiaan Hospital, Oostende, [4] Imelda Hospital, Bonheiden, [5] Hospital Estaing, Clermont-Ferrand, France, [6] Hospital Archet, Nice, France, [7] AZ Sint-Lucas Hospital, Brugge, [8] Academic Medical Center, Amsterdam, Netherlands, [9] UZ Leuven

121 Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn's disease: Pharmacokinetic-pharmacodynamic analysis of TAILORIX.

E. DREESEN (1), G. D'HAENS (2), F. BAERT (3), B. PARIENTE (4), Y. BOUHNİK (5), J. VANDER WOUDE (6), J. MOREAU (7), D. LAHARIE (8), S. VERMEIRE (9), A. GILS (1) / [1] KULeuven, [2] Academic Medical Center, Amsterdam, Netherlands, [3] AZ Delta, Roeselare, [4] Hospital Claude Huriez, Lille, France, [5] Hospital Beaujon, Paris, France, [6] Erasmus MC, Rotterdam, Netherlands, [7] CHU Toulouse, France, [8] Hospital Haut-Lévêque, Bordeaux, France, [9] UZ Leuven

122 Potential diagnostic biomarkers of Ulcerative colitis-associated colorectal dysplasia.

A. MERLI (1), C. MASSOT (1), N. BLÉTARD (2), F. QUESADA CALVO (1), D. BAIWIR (1), G. MAZZUCHELLI (1), N. SMARGIASSO (1), L. SERVAIS (1), C. OURY (1), M. DE PAUW-GILLET (1), E. DE PAUW (1), C. COIMBRA MARQUES (2), A. COLARD (3), A. VIJVERMAN (4), P. DELVENNE (2), M. MEUWIS (1), E. LOUIS (1) / [1] ULiège, [2] CHU de Liège, [3] CHC de Liège, [4] CHR Citadelle de Liège

I23 Golimumab Dried Blood Spot Analysis (GOUDA): A Prospective Trial to Validate Golimumab Concentration Analysis Using the Dried Blood Spot Methodology.

I. DETREZ (1), E. DREESEN (1), G. VAN ASSCHE (2), S. VERMEIRE (2), M. FERRANTE (2), A. GILS (1) / [1] KULeuven, [2] UZ Leuven

I24 Infliximab and Vedolizumab Show a Different Effect on Clot Formation in Inflammatory Bowel Disease Patients.

I. DETREZ (1), E. DREESEN (1), G. VAN ASSCHE (2), S. VERMEIRE (2), M. FERRANTE (2), A. GILS (1) / [1] KULeuven, [2] UZ Leuven

I25 Epidemiology of Clostridium difficile infections in IBD over two decades.

I. DETREZ (1), E. DREESEN (1), G. VAN ASSCHE (2), S. VERMEIRE (2), M. FERRANTE (2), A. GILS (1) / [1] KULeuven, [2] UZ Leuven

I26 Proteomic analysis highlights divergences and convergences between ileal and colonic pathological processes involved in Crohn's ulcers.

N. PIERRE (1), C. REENAERS (2), C. VAN KEMSEKE (2), J. LOLY (2), G. MAZZUCHELLI (1), N. SMARGIASSO (1), D. BAIWIR (1), D. MORSA (1), E. DE PAUW (1), M. MEUWIS (2), E. LOUIS (2) / [1] ULiège, [2] CHU de Liège

I27 Serum proteomic profiling in Crohn's disease patients undergoing ileocolonic resection reveals discriminative inflammatory markers for endoscopic recurrence.

K. MACHIELS, M. DE BRUYN, S. VERSTOCKT, B. VERSTOCKT, G. VAN ASSCHE, A. WOLTHUIS, A. D'HOORE, M. FERRANTE, S. VERMEIRE / UZ Leuven

I28 Quantitative microbiome profiling changes the described dysbiotic state in inflammatory bowel disease.

C. CAENEPEEL (1), S. VIEIRA-SILVA (1), J. SABINO (1), K. MACHIELS (1), G. FALONY (2), M. FERRANTE (3), G. VAN ASSCHE (3), J. RAES (2), S. VERMEIRE (3) / [1] KULeuven, [2] Rega Institute, Leuven, [3] UZ Leuven

129 Illegal gene expression changes are associated with colonic disease activity in patients with ulcerative colitis.

M. VANCAMELBEKE, S. VERSTOCKT, M. FERRANTE, G. VAN ASSCHE, S. VERMEIRE, I. CLEYNEN / KULeuven

130 Low adalimumab serum levels at week 4 provoke immunogenicity and influence therapy outcome in anti-TNF naïve Crohn's disease patients.

B. VERSTOCKT (1), G. MOORS (1), S. BIAN (2), T. VAN STAPPEN (2), S. TOPS (2), V. BALLEET (1), G. VAN ASSCHE (1), S. VERMEIRE (1), A. GILS (1), M. FERRANTE (1) / [1] UZ Leuven, [2] KULeuven

131 Filgotinib (GLPG0634, GS-6034), a JAK-1 Selective Inhibitor, Significantly Reduces Gut Tissue pSTAT3 in Crohn's Disease Patients.

G. DE HERTOOGH (1), G. CHEN (2), D. FRENCH (2), E. HUNTZICKER (2), A. VAN DER AA (3), T. VAN KAEM (3), P. HARRISON (3), C. TASSET (3), R. GALIEN (4), Y. PAN (2), B. FEAGAN (5), W. SANDBORN (6), S. VERMEIRE (1) / [1] UZ Leuven, [2] Gilead Sciences, Inc, Foster City, USA, [3] Galapagos NV, Mechelen, [4] Galapagos SASU, Romainville, France, [5] Robarts Research Institute, London, Ontario, Canada, [6] University of California San Diego, USA

132 Effect of disease duration and location on clinical remission in Crohn's disease patients treated with filgotinib, a selective JAK1 inhibitor: post-hoc analysis from the Phase 2 FITZROY study.

S. VERMEIRE (1), A. COLARD (2), V. MULS (3), M. DE VOS (4), A. VIJVERMAN (5), O. DEWIT (6), A. VAN DER AA (7), C. JAMOUL (7), C. TASSET (7), P. HARRISON (7), G. D'HAENS (8) / [1] UZ Leuven, [2] Clinique Saint-Joseph, Liège, [3] CHU Saint-Pierre, Brussels, [4] UZ Gent, [5] CHR Citadelle, Liège, [6] UCL Saint-Luc Brussels, [7] Galapagos NV, Mechelen, [8] Academic Medical Center, Amsterdam, Netherlands.

133 Serum markers predict outcome to ustekinumab in patients with refractory Crohn's diseases and provide insides in the mechanism of action.

B. VERSTOCKT (1), S. VERMEIRE (1), S. VERSTOCKT (2), B. CREYNS (1), N. ARDESHIR DAVANI (2), C. BREYNAERT (2), G. VAN ASSCHE (1), M. FERRANTE (1) / [1] UZ Leuven, [2] KULeuven

134 The interaction between intestinal permeability disturbances and inflammation in a chronic colitis mouse model, studied over time.

H. VAN SPAENDONK, J. DE MAN, S. FRANQUE, H. DE SCHEPPER, B. DE WINTER / UZAntwerpen.

135 Beclomethasone dipropionate is effective for microscopic colitis: results of an open label multicenter study (COLCO).

T. DE CORTE (1), E. JANSSENS (1), K. THORREZ (2), A. D'HONDT (1), K. DEJAEGER (3), F. D'HEYGERE (4), B. VAN BESIEEN (2), L. HARLET (1), H. PEETERS (5), W. VANMOERKERCKE (4), P. VAN HOOTEGEM (6), F. BAERT (1) / [1] AZ Delta, Roeselare, [2] Jan Yperman Hospital, Ieper, [3] Sint-Jozefskliniek, Izegem, [4] AZ Groeninge, Kortrijk, [5] AZ Sint-Lucas, Gent, [6] AZ Sint-Lucas Brugge

E - POSTERS

136 The clinical utility of a multi-marker serum test for assessment of ulcerations in infliximab treated patients with Crohn's disease.

M. DE BRUYN (1), T. BESSISSOW (2), V. KONDRAGUNTA (3), A. JAIN (3), I. ARIJS (4), G. VAN ASSCHE (5), M. FERRANTE (5), G. OPDENAKKER (6), S. VERMEIRE (5) / [1] KULeuven, [2] McGill University, Montreal, Canada, [3] Prometheus Laboratories Inc., San Diego, USA, [4] Jessa Hospital, Hasselt, [5] UZ Leuven, [6] Rega Institute for Medical Research

137 A prospective trial to evaluate the feasibility of a mobile app in patients with inflammatory bowel disease under maintenance therapy.

S. COENEN, E. WEYTS, P. GEENS, E. NIJNS, R. VAN DURM, M. FERRANTE, S. VERMEIRE, B. VAN DEN BOSCH, G. VAN ASSCHE / UZ Leuven

138 Right colectomy and ileocaecal resections for colorectal cancer and Crohn's disease: assessment of postoperative results over a 5-year period.

D. LEONARD, Y. HAMIDA, S. BARBOIS, C. REMUE, R. BACHMANN, N. ABBES ORABI, M. BLANCO, O. DEWIT, M. DENIS, A. KARTHEUSER / UCL Saint-Luc Brussels

E-Poster Area

Belgian Microbiota and
Helicobacter Study Group

E - POSTERS

H01 Helicobacter Pylori eradication: use of the PDCA cycle to achieve real world data in the Ghent region and to improve eradication outcome.

Helicobacter Pylori eradication: use of the PDCA cycle to achieve real world data in the Ghent region and to improve eradication outcome.

D. BAERT, P. BURVENICH, C. VAN STEENKISTE, E. MONSAERT, E. VANDERSTRAETEN, K. RASQUIN, P. DEWINT, N. STOENS / AZ Maria Middelares, Gent

H02 Facteurs associés a la séroprévalence de l'Helicobacter pylori à Bukavu, ville provinciale de l'Est de la République Démocratique du Congo.

FACTEURS ASSOCIES A LA SEROPREVALENCE DE L'HELICOBACTER PYLORI A BUKAVU, VILLE PROVINCIALE DE L'EST DE LA RD CONGO.

P. NGOMA (1), B. MATUNGO (2), D. LUPANDE (2), C. MALU (1), P. KENGIBE (1), A. TSHIMPI (1), R. FIASSE (3), H. DAHMA (4), E. TSHIBANGU (5), J. KABINDA (6), B. LONGO-MBENZA (1), Y. MIENJE (4) / [1] Cliniques Universitaires de Kinshasa (CUK), Congo, [2] Hôpital provincial général de référence de Bukavu, Congo, [3] UCL Saint-Luc, Brussels, [4] CHU Brugmann, Brussels, [5] Oita University, Yufu, Japan, [6] Université Catholique de Bukavu, Congo

TIFFANY/
SHAH
(2nd Floor) | Young Belgian Association
for the Study of the Liver
(Young BASL)

SESSION 1: Exchanging experiences in basic and clinical research in hepatology: from ethics and methodology to results and clinical applicability
CHAIRS: Inge Mannaerts (UZ Brussel), Rob Bielen (Hasselt University)

-
- 14:00** **BASL best clinical paper MSD 2017 “Intensive Enteral Nutrition Is Ineffective for Patients**
Christophe Moreno /ULB Erasme Brussels
-
- 14:20** **BASL best basic paper MSD 2017 “A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis.”**
Xavier Verhelst /UZ Gent
-
- 14:40** **Invited Lecture: Animal models in liver disease: from law to practice.**
Renee Tolba / Aachen, Germany
-
- 15:25** **Coffee break**
-
- 15:45** **Starter’s talk: “Systems Serology Analysis of Human Alcoholic Liver Diseases”.**
Antonella Putignano /ULB Erasme Brussels
-
- 15:55** **Starter’s talk: “The role of the intrahepatic vascular resistance and its underlying mechanisms in the pathophysiology of NAFLD”.**
Denise van der Graaff /UAntwerpen
-
- 16:05** **Invited Lecture: “Antiviral therapy: from bench to bedside.”**
Johan Neyts /Rega Institute, Leuven
-
- 16:50** **Closing remarks**

Need to explain the exocrine pancreatic insufficiency to your patients ?

A guide exists with informations & animations to support you and help them for a better understanding !



www.e-guide-visuel-insuffisance-pancreatique-exocrine.be
www.visuele-e-gids-exocriene-pancreasinsufficientie.be

FR



NL



With the kind support of

Belgian
Pancreatic
Club



Mylan®

Seeing
is believing

SESSION 1

Chairs: Pierre Deprez (UCL Saint-Luc Brussels), Geert Roeyen (UZAntwerpen)

14:00 **Invited Lecture: Diagnosis of pancreatic cystic lesions.
The view of the clinician – The view of the pathologist.**

M. Delhaye, P. Demetter / ULB Erasme, Brussels

14:30 **P 01** **Endoscopic necrosectomy a single center experience.**

A. Taha, T. Aouattah, R. Yeung, T. Moreels, H. Piessevaux, P. Deprez / UCL Saint-Luc Brussels

14:45 **P 02** **Long term outcome of patients with pancreatic duct disruption.**

M. Arvanitakis, A. Bourguignon, M. Delhaye, J. Devière, C. Matos / ULB Erasme Brussels, Champalimaud Clinical Center, Lisbon, Portugal

15:00 **P 03** **Improvement of pancreatic endocrine function after endoscopic treatment
of chronic pancreatitis.**

S. Kautbally, M. Hermans, T. Moreels, T. Aouattah, E. Perez-Cuadrado-Robles, P. Deprez / UCL Saint-Luc Brussel

15:15 **Invited Lecture: Management of autoimmune pancreatitis in 2018.**

J. van Hooft / Amsterdam, Netherlands

15:45 **Coffee break**

SESSION 2

CHAIRS: Pierre Eisendrath (ULB Erasme Brussels), Jean-Philippe Loly (CHU Liège)

16:10 **P 04** **Severe panniculitis and polyarthrititis.**

A. Raptis, M. Plier, N. Jabbour, P. Durez, M. Komuta / UCL Saint-Luc Brussels

16:20 **P 05** **A rare variant of conventional pancreatic ductal adenocarcinoma.**

L. Verset (1), S. Debroux (2), P. Eisendrath (3), E. Toussaint (4), R. Marechal (4), J.-L. Van Laethem (1), F. Charara (2), J. Closset (1), P. Loi (1), M. Pezzullo (1), M. Delhaye (1), M. Arvanitakis (1), P. Demetter (1) / [1] ULB Erasme Brussels, [2] CHU Tivoli, La Louvière, [3] CHU Saint-Pierre, Brussels, [4] CHU de Charleroi, Hôpital Marie Curie

16:30 **P 06** **A rare cause of repetitive acute pancreatitis.**

A. Dupin, J. Loly, P. Gast, T. Mesureur, E. Louis / CHU Sart Tilman, Liège

16:40 **P 07** **EUS guided pancreaticogastrostomy.**

C. Amicone, P. Gast, JP Loly, E. Louis / CHU Sart Tilman, Liège

16:50 **A rare but morphological characteristic cystic lesion of the pancreas.**

A. Hoorens, L. Ferdinande, F. Berrevoet, P. Smeets / UZ Gent

SESSION 1: Interactive Case Reports

CHAIRS: Luisa Vonghia (UZA), C. Van Kemseke (CHU Liège)www

14:00 C 01 An unusual cause of bleeding in a cirrhotic patient.

M. STRUYVE (1), G. ROBAEYS (2) / [1] UZ Leuven, [2] ZOL, Genk

14:20 C 02 A case of acute hepatitis under Nivolumab treatment.

L. WUYTS, A. JANSSENS, L. VONGHIA, P. MICHIELSEN, J. VAN MEERBEECK, S. FRANQCQUE, T. VANWOLLEGHEM / UZAntwerpen

14:40 C 03 Endoscopic submucosal dissection of a suspicious esophageal lesion

L. MANS (1), P. EISENDRATH (2), L. VERSET (1), P. DEMETTER (1), V. HUBERTY (1), A. DEMOLS (1), J. DEVIERE (1), A. LEMMERS (1) / [1] ULB Erasme Brussels, [2] CHU Saint-Pierre, Brussels

15:00 C 04 Terminal ileitis after kidney transplantation: Crohn's disease or other cause?

E. MOTTÉ, L. PIPELEERS, J. SENNESAEL, D. URBAIN, F. MANA / UZ Brussel

15:20 Coffee Break

15:40 C 05 Uncommon cause of cholangiopathy in a cirrhotic patient: EUS finding

S. MUPINGU (1), M. FERNANDEZ Y VIESCA (1), G. VERSET (1), M. PALAZZO (2), P. EISENDRATH (1) / [1] ULB Erasme Brussels, [2] Hôpital Beaujon, Clichy, France

16:00 C 06 Infectious complications in a patient with automated low-flow ascites pump: a unique case report

M. SAERENS (1), T.VANWOLLEGHEM (1), P.MICHIELSEN (1), D. SPRENGERS (2), L. VONGHIA (1), S. FRANQCQUE (1) / [1] UZAntwerpen, [2] GZA St.-Augustinus Hospital, Antwerp

16:20 C 07 Acute esophageal mucosal damage after Lugol staining

Q. VAN THILLO (1), A. VANDEN BULCKE (1), M. COOL (2), G. LAMBRECHT (2), G. DEBOEVER (2)/[1] UZ Leuven, [2] AZ Damiaan, Oostende

16:40 C 08 A case of portal vein aneurysm

C. DE VLOO, W. MEERSSEMAN, G. MALEUX, S. HOUTHOOFD, K. OP DE BEECK, W. LALEMAN, F. NEVENS, L. VERBEKE, H. VAN MALENSTEIN, S. VAN DER MERWE, C. VERSLYPE / UZ Leuven

Ultra-Sound Courses Florentine room - 2nd Floor

THIS YEAR, **the Belgian week** organizes once again a practical, hands-on sessions in ultrasound on **Wednesday** and **Thursday** afternoon.

Wednesday afternoon the course will focus on **normal anatomy and abdominal pathology** for trainees in ultrasound. Participants will be divided according to the level of experience: Normal anatomy will be demonstrated on healthy volunteers for absolute beginners. Experienced participants will be demonstrated abdominal pathology on simulators.

This course offers the possibility to get acquainted with ultrasound recordings of rare (and not so rare) gastro-intestinal disorders, to improve and upgrade your ultrasound skills. Depending on the interests of the participants, we will focus on liver tumors, vascular liver diseases, liver cirrhosis and its complications, inflammatory bowel disorders, general bowel disorders...

This course has been organized successfully during numerous international meetings (e.g. **EASL**).



Welcome Drink



WEDNESDAY 21 FEBRUARY

17h00 - 18h30

IN THE EXHIBITION AREA

BWGE 2018

Industry-sponsored satellite breakfast symposium

CHANGING PERSPECTIVES IN PRIMARY BILIARY CHOLANGITIS (PBC)

Thursday 22 February 2018 | 08:00–08:30

**Teun meeting room, 3rd floor
Hilton Hotel, Antwerp, Belgium**

The recent update to the EASL clinical practice guidelines for the diagnosis and management of patients with PBC is contributing to a change in perception of the disease and in understanding of how patients with PBC should be managed.

This educational symposium will explore the epidemiology, patient treatment and the emerging therapeutic options and the clinical impact of the new guidelines. We hope you will be able to join us for an interactive and engaging discussion about this evolving therapy area.

Breakfast will be provided.

Intercept 

This event has been organised and funded
by Intercept Pharma Nederland BV
Kamperingweg 45d, 2803PE, Gouda (NL)
+31 182 71 50 57
info.benelux@interceptpharma.com

08:00 **Breakfast Satellite Symposium INTERCEPT**

Invited Speakers: Prof. F. NEVENS, (UZ Leuven) / Prof. C. MORENO, (ULB Erasme Brussels)

SESSION 1

CHAIRS: Anja Geerts (UZGent), Jean Delwaide (ULiège)

08:30 **A 01** **Screening for Hepatitis C at the emergency department: baby boomers should also be screened in Belgium.**

R. BIELEN (1), C. KREMER (1), Ö. KOC (1), D. HENDRICKX (1), P. VANELDEREN (2), N. HENS (1), F. NEVENS (3), G. ROBAEYS (2) / [1] Hasselt University, [2] ZOL, Genk, [3] UZ Leuven

08:40 **A 02** **The thrombogenic risk induced by intraportal infusion of Adult Derived Human Liver Stem/Mesenchymal Cells in Wistar rats can be controlled with a combination of anticoagulant drugs, heparin and bivalirudin.**

L. COPPIN (1), M. ROZZI (2), M. KOMUTA (1), S. HORMAN (2), E. SOKAL (1), X. STÉPHENNE (1) / [1] UCL Saint-Luc Brussels, [2] UCL, IREC

08:50 **A 03** **Liver stiffness and steatosis evaluation by transient elastography in obese patients: baseline results analysis from a prospective Belgian study.**

N. LANTHIER, S. HIEL, J. RODRIGUEZ, B. DELIRE, M. DE BARCY, J. THISSEN, N. ELZENNE / UCL Saint-Luc Brussels

09:00 **A 04** **Small for Size Syndrome and Hypoxia: lessons learned from the associated liver partition and portal vein ligation for staged hepatectomy (ALPPS procedure in rats).**

A.DILI (1), V. LEBRUN (2), C. BERTRAND (1), I. LECLERCQ (2) / [1] CHU UCL Namur, [2] UCL, Laboratory of Hepato- Gastroenterology

09:10 **A 05** **A new "treatment-response score" for auto immune hepatitis is predictive of long- term event-free survival and overall survival. A multicenter Belgian cohort study.**

A.SIMOEN (1), J. SCHOUTEN (2), C. VAN STEENKISTE (3), A. GEERTS (1), H. VAN VLIERBERGHE (1), X. VERHELST (1) / [1] UZ Gent, [2] AZ Nikolaas, Sint-Niklaas, [3] AZ Maria Middelaers, Gent

09:20 **A 06** **Generation of a unique liver progenitor cell gene signature to identify LPCs and LPC activation in chronic liver diseases.**

S. VERHULST (1), P. SANCHO-BRU (2), A. CEULEMANS (3), T. ROSKAMS (3), L. VAN GRUNSVEN (1) / [1] VUB, Jette, [2] Investigaciones Biomédicas August Pi i Suñer, Spain, [3] UZ Leuven

09:30 A 07 The outcome of acute-on-chronic liver failure in the intensive care is similar to a propensity matched ICU population without liver disease.

S. VAN DER MERWE (1), P. MEERSSEMAN (2), L. LANGOUCHE (1), M. MEKEIRELE (2), H. KORF (1), J. DU PLESSIS (1), D. CASSIMAN (1), W. LALEMAN (2), F. NEVENS (2), A. WILMER (2), G. VAN DEN BERGHE (1) / [1] KULeuven, [2] UZ Leuven

09:40 A 08 Transcriptional repressors Zeb1 and Zeb2 regulate collagen production in drug-induced hepatic stellate cell activation in mice.

I. MANNAERTS, L. STRADIOT, N. EYSACKERS, L. VAN GRUNSVEN / VUB, Jette

09:50 A 09 Individualized prediction of the risk of liver-related death in patients with alcoholic cirrhosis.

A. MAROT (1), J. HENRION (2), J. KNEBEL (3), F. SIGNY (3), E. TREPO (4), C. MORENO (4), P. DELTENRE (5) / [1] CHU UCL Namur, [2] Hôpital de Jolimont, Haine- Saint-Paul, [3] Université de Lausanne, Switzerland, [4] ULB Erasme Brussels, [5] Clinique Saint-Luc Bouge, Namur

10:00 COFFEE BREAK

SESSION 2

CHAIRS: Sergio Negrin-Dastis (UCL Saint-Luc, Brussels), Xavier Rogiers (UZGent)

10:30 A 10 Is it too early to expand beyond the Milan Criteria for liver transplantation? A retrospective, multicentric study in Belgium.

H. DEGROOTE (1), E. CALLEBOUT (1), J. DE KERVEL (2), J. SCHREIBER (3), J. PIRENNE (2), C. VERSLYPE (2), D. YSEBAERT (4), P. MICHIELSEN (4), V. LUCIDI (3), C. MORENO (3), O. DETRY (5), J. DELWAIDE (5), J. LERUT (6), G. DAHLQVIST (6), R. TROISI (1), H. VAN VLIERBERGHE (1) / [1] UZ Gent, [2] UZ Leuven, [3] UZ Brussel, [4] UZAntwerpen, [5] CHU Liège, [6] UCL Saint-Luc Brussels

10:42 A 11 Transcriptomic profiling of intrahepatic B cells suggests a B-cell impairment in the Immune Active phase of Chronic Hepatitis B.

S. VAN HEES (1), J. HOU (2), A. GROOTHUISMINK (2), K. KREEFFT (2), S. BOURGEOIS (3), L. VONGHIA (1), S. FRANCQUE (1), P. MICHIELSEN (1), A. BOONSTRA (2), T. VANWOLLEGHEM (1) / [1] UZAntwerpen, [2] Erasmus Medical Center, Rotterdam, Netherlands, [3] ZNA Antwerpen

Abbvie has the great pleasure to invite you to our symposium during the XXVIIIth edition of the Belgian Week of Gastroenterology

Towards the eradication of HCV



Thursday February 22, 2018 At 12h00



Moderators

- ▶ **Prof. Christophe Moreno**
Erasme Hospital & president of BASL
- ▶ **Prof. Wim Laleman**
UZ Leuven



Screening and awareness initiatives in Belgium

- ▶ **Prof. Isabelle Colle**, ASZ Aalst
- ▶ **Dr. Boris Bastens**, CHC Liège
- ▶ **Prof. Jeoffrey Schouten**, AZ Nikolaas
- ▶ **Dr. Christophe Vansteenkiste**, AZ Maria Middelaers Gent

Satellite Symposium
MSD Belgium

BEYOND THE EFFICACY OF HCV TREATMENTS, WHAT DOES REALLY MATTER ? A PROS AND CONS DEBATE

Speakers :

Dr. Nancy Reau

Rush University Medical Center, Chicago, U.S.

Dr. Ashley Brown

Imperial College, London, U.K.

Moderator :

Prof. Anja Geerts

UZ Gent, Belgium

Thursday - February 22, 2018

13.15 – 14.00

10:54 A 12 **Short and long-term survival of patients suffering from non-severe alcoholic hepatitis.**

G. ENGLEBERT (1), D. DEGRÉ (1), T. GUSTOT (1), P. DEMETTER (1), A. MAROT (2), P. DELTENRE (2), E. TREPO (1), C. MORENO (1) / [1] ULB Erasme Brussels, [2] CHUV, Lausanne, Switzerland

11:06 A 13 **Angiopoietin-2 as therapeutic target for pathological angiogenesis and inflammation in non-alcoholic steatohepatitis.**

S. LEFERE (1), F. VAN DE VELDE (1), S. RAEVENS (1), S. VAN CAMPENHOUT (1), A. VANDIERENDONCK (1), S. NEYT (2), C. VANHOVE (1), C. VANSTEENKISTE (3), A. HOORENS (4), C. CASTELEYN (4), X. VERHELST (1), H. VAN VLIERBERGHE (1), B. LAPAUW (1), A. GEERTS (1), L. DEVISSCHER (1) / [1] UZ Gent, [2] Molecubes, Gent, [3] Maria Middelaers Ziekenhuis, Gent, [4] UGent

11:18 A 14 **Long-term outcome in patients with acute liver failure.**

A. PUTIGNANO (1), F. FIGORILLI (2), B. AGARWAL (3), R. JALAN (3) / [1] ULB Erasme Brussels, [2] Azienda Ospedaliero-Universitaria di Cagliari, Italy, [3] Royal Free Hospital, London, UK

11:30 **BELIAC Lecture: Surgical management of early HCC.**

Chair: Olivier Detry (ULiège)

Resection is the first option:

Valerio Lucidi (ULB Brussels)

Liver transplantation is the first option:

Jacques Pirenne (KULeuven)

12:00 **Satellite Symposium Abbvie**

SCHOUTEN, Invited Speakers: Prof. I. COLLE, (ASZ Aalst) / Dr. B. BASTENS, (CHC Liège) / Prof. J. (AZ Nikolaas) / Dr C. VANSTEENKISTE, (AZ Maria Middelaers Gent)

12:45 **LUNCH**

13:15 **Satellite Symposium MSD**

Invited Speakers: Dr. N. REAU, Rush University Medical Center, Chicago (USA) / Dr A. BROWN, Imperial College, London (UK)

SESSION 3

CHAIRS: Thomas Vanwolleghem (UZAntwerpen), Dr Bonacorsi (UCL Saint-Luc, Brussels)

14:00 A 15 The effects of methoxamine and endothelin-1 on the increased transhepatic pressure gradient in a rat model of severe steatosis.

D. VAN DER GRAAFF (1), W. KWANTEN (1), J. DE MAN (2), B. DE WINTER (2), P. MICHELSEN (1), S. FRANCKUE (1) / [1] UZAntwerpen, [2] UAntwerpen

14:12 A 16 Risk of hepatocellular cancer and fibrosis evolution in HCV patients treated with direct acting antiviral agents.

C. HAMOIR, P. STARKEL, G. DAHLQVIST, Y. HORSMANS, N. LANTHIER / UCL Saint-Luc Brussels

14:24 A 17 The combination of N-acetylcysteine and anti-MT antibodies as novel therapy for acetaminophen-induced liver injury.

L. DEVISSCHER (1), D. LAUKENS (1), H. VAN EECKHOUTTE (1), S. RAEVENS (1), S. LEFERE (1), A. HOORENS(1), X. VERHELST (1), M. LYNES (2), A. GEERTS (1), H. VAN VLIERBERGHE (1) / [1] UZ Gent, [2] University of Connecticut, Storrs, USA

14:36 A 18 The impact of pulmonary arterial hypertension therapy in patients with portopulmonary hypertension: a single tertiary center cohort analysis.

F. NEVENS, H. PEETERS, W. LALEMAN, C. VERSLYPE, S. VAN DER MERWE, D. MONBALIU, J. PIRENNE, M. DEL-CROIX / UZ Leuven

14:48 A 19 Cytotoxic CD8 T lymphocytes are associated with "active" NASH: from the blood to the liver.

CHAIR: Christophe Moreno (ULB Erasme, Brussels)

15:00 MARC HAUTEKEETE LECTURE : Diagnostic approach of cholestasis: When it is neither PBC nor PSC.

Vincent Leroy (CHU Grenoble, France)

15:30 COFFEE BREAK



ZEPATIER[®]

(elbasvir and grazoprevir)



MSD Belgium BVBA/SPRL Lynx Binnenhof 5, Clos du Lynx – Brussel 1200 Bruxelles.
INFC-1204328-0012 • Date of last revision 01/2018

		3 rd FLOOR	
		ROOMS	
		BELLE EPOQUE	LIJN
WEDNESDAY 21/02	LUNCH 12h00-14h00	Exhibition Area	
		Exhibition Area	Satellite Symposium JANSSEN-CILAG 13h15-14h00
	AFTERNOON		BIRD Basic
	Coffee Break	Exhibition Area	
	AFTERNOON		BIRD Basic
	17h00-17h45	Get together Reception	Satellite Symposium PFIZER 17h00-17h45
17h45-18h30	General Assembly BIRD		
THURSDAY 22/02	MORNING		
	MORNING		Case Reports
	Coffee Break	Exhibition Area	
	MORNING		Case Reports
	LUNCH 12h00-14h00	Oral Top Basic Posters 12h15-13h	
		Exhibition Area	
			Satellite Symposium TAKEDA 13h15-14h00
	AFTERNOON		BIRD Clinical
	Coffee Break	Exhibition Area	
	AFTERNOON		BIRD Clinical
16h45-18h30			
FRIDAY 23/02	MORNING		
			Working Group of Digestive Pathology
	Coffee Break	Exhibition Area	
	MORNING		Working Group of Digestive Pathology
	LUNCH 12h00-14h00	Oral Top Clinical Posters 12h15-13h	
		Exhibition Area	
		Award Ceremony 13h00-13h15	Satellite Symposium BMS Oncology 13h15-14h00
	AFTERNOON		Brohée Lecture
			Working Group of Digestive Pathology
Coffee Break	Exhibition Area		
AFTERNOON		Working Group of Digestive Pathology	
18h00-18h45			

TEUN	SANCY	2 nd FLOOR	
		TIFFANY/SHAH	FLORENTINE
Belgian Pancreatic Club	Case Reports	Young BASL	
Belgian Pancreatic Club	Case Reports	Young BASL	
			ULTRA SOUND Course 17h00-19h00
Breakfast Symposium INTERCEPT 8h00-8h30			
BASL		GIREM	
BASL		GIREM	
Satellite Symposium ABBVIE 12h00-12h45			
Satellite Symposium MSD 13h15-14h00			
BASL	BSGIE	GIREM	
BASL	BSGIE	GIREM	ULTRA SOUND Course 17h00-19h00
Satellite Symposium GILEAD 16h45-17h30	Satellite Symposium PFIZER/BMS 17h20-18h05	Acta GA 17h30-18h30	
Breakfast Symposium ELI LILLY 8h00-8h30			
BGDO	Proctology	BINASTORIA Meeting	
BGDO	Proctology	BINASTORIA Meeting	
Satellite Symposium SERVIER 12h00-12h45	GBS-VBS General Assembly	BINASTORIA Meeting	
BSGIE Live Transmission Session	BeSPGHAN	BINASTORIA Live Transmission Session	
BSGIE Live Transmission Session	BeSPGHAN	BINASTORIA Live Transmission Session	

GILEAD SATELLITE SYMPOSIUM

IS NASH THE NEXT HCV?

What can we learn from our Hepatitis C experience to better manage our NASH patients?

SPEAKER

Professor Philippe Mathurin

Head of the Department of Hepato-Gastroenterology
Centre Hospitalier Régional Universitaire de Lille, France

MODERATOR

Professor Sven Francque

Head of the Department of Hepato-Gastroenterology
University Hospital Antwerp, Belgium

THURSDAY 22ND FEBRUARY

From 16:45 to 17:30

Hilton Antwerp, Room Teun



SESSION 4

CHAIRS: Peter Michielsen (UZAntwerpen), Peter Stärkel (UCL Saint-Luc Brussels)

16:00 A 20 Insulin resistance in cirrhotic patients : results from a large prospective study.
F. CLAREMBEAU (1), P. STARKEL (1), G. DAHLQVIST (1), I. LECLERCQ (2), N. LANTHIER (1) / [1] UCL Saint-Luc Brussels, [2] UCL Saint-Luc, Institut de Recherche Expérimentale et Clinique

16:10 A 21 Fibroscan is a useful and reliable tool to rule out advanced liver fibrosis and severe portal hypertension in alcoholic patients.
M. SALAVRAKOS, N. LANTHIER, P. STARKEL / UCL Saint-Luc Brussels

16:20 A 22 The effects of NO modulators on the increased transhepatic pressure gradient in a rat model of severe steatosis.
D. VAN DER GRAAFF (1), W. KWANTEN (1), J. DE MAN (2), B. DE WINTER (2), P. MICHELSEN (1), S. FRANCCQUE (1) / [1] UZAntwerpen, [2] UAntwerpen, Laboratory of Experimental Medicine and Pediatrics

16:30 A 23 Estimation of the future liver remnant function is a better tool to predict post-hepatectomy liver failure than platelet-based liver scores.
T. CHAPPELLE, B. OP DE BEECK, A. DRIESSEN, G. ROEYEN, B. BRACKE, V. HARTMAN, I. HUYGHE, M. PEETERS, S. FRANCCQUE, D. YSEBAERT / UZAntwerpen

16:40 BASL Awards for best Basic and Clinical work presented.

16:45 Satellite Symposium GILEAD

Invited Speaker: Prof. P. MATHURIN

17:30 BASL General Assembly

A24 Morphological features of spontaneous bacterial peritonitis in cirrhotic patients.

D. HAURYLENKA, T. HAURYLENKA / Republican Research Center for Radiation Medicine and Human Ecology, Gomel, Belarus

A25 Screening for hepatitis C viral infection in a non-urban primary care facility in Flanders.

G. DEVOLDER (1), M. DE WILDE (1), L. GODERIS (1), D. ANN (1), E. SPILLEBEEN (1), A. GEERTS (2), A. DERESE (2), H. VAN VLIERBERGHE (2), X. VERHELST (2) / [1] Artsenpraktijk Vierschaar, Lendeledede, [2] UZ Gent

A26 Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis.

A. MAROT (1), M. DUBOIS (2), E. TREPO (3), C. MORENO (3), P. DELTENRE (4) / [1] CHU UCL Namur, Yvoir, [2] CHUV, Lausanne, Switzerland, [3] ULB Erasme Brussels, [4] UCL Saint-Luc Bouge, Namur

A27 Effects of GLP-1 receptor polymorphisms on adolescent obesity.

M. MARALANI / UZAntwerpen

A28 Under constant injury ductular-derived hepatocytes clonally grow as robust carcinoma genesis-resistant population
A29 Point-of-care diagnostic tests for HBV and HCV are associated with a higher linkage to care in an Asian migrant population.

R. MANCO (1), L. CLERBAUX (1), M. BOU NADER (2), C. SEMPOUX (3), C. DESDOUETS (2), Y. HORMSANS (1), I. LECLERCQ (1) / [1] UCL, Brussels, [2] Université Paris-René Descartes, France, [3] CHUV, Lausanne, Switzerland

A29 Point-of-care diagnostic tests for HBV and HCV are associated with a higher linkage to care in an Asian migrant population.

E. HO (1), P. MICHIELSEN (1), P. VAN DAMME (2), I. VELDHUIJZEN (3), T. VANWOLLEGHEM (1) / [1] UZ, Antwerpen, [2] UAntwerpen, [3] Municipal Public Health Service Rotterdam-Rijnmond, Netherlands

A30 Liver transplantation in Jehovah's witnesses.

M. VANDERMEULEN, N. MEURISSE, P. DAMAS, A. KABA, A. LAMPROYE, J. DELWAIDE, J. JORIS, P. HONORÉ, O. DETRY / CHU Liège

A31 Alveolar echinococcosis is now endemic in southern Belgium.

A. CAMBIER (1), P. LEONARD (1), B. LOSSON (2), M. HAYETTE (1), J. GIOT (1), N. BLETARD (1), P. MEUNIER (1), R. HUSTINX (1), N. MEURISSE (1), J. DELWAIDE (1), P. HONORE (1), O. DETRY (1) / [1] CHU Liège, [2] ULiège

A32 Descriptive epidemiologic data on liver cancer in Belgium, 2004-2025.

F. CALAY (1), K. HENAU (1), J. FRANCCART (1), N. VAN DAMME (1), C. VERSLYPE (3), L. VAN EYCKEN (1) / [1] Belgian Cancer Registry, Brussel, [2] UZ Leuven

A33 Multivisceral transplantation for diffuse portomesenteric thrombosis: a case series.

E. CANOVAI, L. CEULEMANS, G. DE HERTOIGH, M. HIELE, M. SAINZ-BARIGA, I. JOCHMANS, T. VANUYTSEL, D. MONBALIU, J. PIRENNE / UZ Leuven

E - POSTERS

A34 Cu isotope ratio shifts in common bile duct ligated mice and correlates with the degree of cholestatic-induced liver disease.

S. VAN CAMPENHOUT (1), M. COSTAS-RODRÍGUEZ (2), A. HASTUTI (2), S. RAEVENS (1), A. GEERTS (1), X. VERHELST (1), F. VANHAECKE (2), H. VAN VLIERBERGHE (1), L. DEVISSCHER (1) / [1] UZ Gent, [2] UGent

A35 CD4+ ROR γ t+ T cells, CD4+ T-bet+, CD4+ CD25+ Foxp3+ T cells and CD8+ T cells are differentially altered in liver and adipose tissue of mice fed a high-fat high-fructose diet in a time-dependent manner.

M. VAN HERCK (1), L. VONGHIA (2), P. MICHELSEN (2), C. BRIDTS (3), D. EBO (1), J. DE MAN (1), B. DE WINTER (1), S. FRANQUE (2) / [1] UAntwerpen, [2] UZAntwerpen

A36 Who to screen for hepatitis C in Belgium? Cost-effectiveness study of comprehensive hepatitis C screening in four target groups.

L. OPSTAELE (1), S. BOURGEOIS (2), C. MORENO (3), F. NEVENS (4), H. VAN VLIERBERGHE (5) / [1] ANZ Medical Writing, Oostende, [2] ZNAntwerpen, [3] ULB Erasme Brussels, [4] UZ Leuven, [5] UZ Gent

A37 Retrospective analysis of HCV infected individuals in a Belgian Regional Hospital.

L. BRUWIER, G. BASTENS, N. CIELNIASZEK, D. GRAAS, B. BASTENS / CHC Clinique Saint-Joseph, Liège

A38 The impact of intra-patient variability in tacrolimus pre-dose concentrations on patient outcomes in pediatric liver transplantation recipients.

C. DEFRAQCQ (1), N. DE WILDE (1), A. RAES (2), M. VAN WINCKEL (2), S. VAN BIERVLIET (2), S. VANDE VELDE (2), X. ROGIERS (2), A. PRYTULA (2), R. DE BRUYNE (2) / [1] UGent, [2] UZ Gent

A39 Loss-to-follow-up is an important problem in the diagnosis and follow-up of hepatitis C.

W. VERLINDEN (1), S. FRANQUE (1), T. HOLVOET (2), S. VAN HEES (3), C. COTTIGNIE (3), V. WIJTVLIET (3), L. VONGHIA (1), P. MICHELSEN (1), T. VANWOLLEGHEM (1) / [1] UZAntwerpen [2] AZ Nikolaas, Sint-Niklaas, [3] UAntwerpen

A40 The association between chronic hepatitis C infection and colon cancer: a nationwide case-control study.

N. LE / Taipei Medical University, Taiwan (Province of China)

A41 Estimation of the future liver remnant function supports parenchyma-saving hepatectomy combined with hepatic vein resection and reconstruction.

T. CHAPPELLE, B. OP DE BEECK, G. ROEYEN, V. HARTMAN, B. BRACKE, D. YSEBAERT / UZ Antwerpen

A42 Estimation of the future liver remnant function prior to hepatectomy may guide the indication for portal vein occlusion and avoid post-hepatectomy liver failure: a prospective interventional study.

T. CHAPPELLE (1), B. OP DE BEECK (2), G. ROEYEN (3), B. BRACKE (3), V. HARTMAN (3), I. HUYGHE (4), S. FRANQUE (5), P. MICHELSEN (5), D. YSEBAERT (3) / [1] UAntwerpen / UZAntwerpen

SESSION 1

CHAIRS: B. De Winter (UAntwerpen), G. Boeckxstaens (KULeuven)

9:00 B 01 Predictors for colonic manometry outcome related to high-amplitude propagating sequences.

J. PANNEMANS (1), I. DEMEDTS (2), A. D'HOORE (2), H. DE SCHEPPER (3), I. HOFFMAN (2), T. VANUYTSEL (1,2), J. TACK (1,2) / [1] KULeuven, [2] KULeuven – UZ Leuven, [3] UZ Leuven

9:15 B 02 Fecal microbiota transplantation in irritable bowel syndrome with predominant abdominal bloating: results from a double blind, placebo-controlled, randomized controlled trial.

T. HOLVOET (1), M. JOOSSENS (2), J. BOELENS (1), E. CHRISTIAENS (1), L. HEYERICK (1), B. VERHASSELT (1), M. DE VOS (1), P. HINDRYCKX (1), J. RAES (2), D. DE LOOZE (1) / [1] UZ Gent, [2] KULeuven

9:30 B 03 Effects of Nafamostat Mesylate on intestinal permeability and bacterial translocation in an experimental model of sepsis.

P. PLAECHE (1), J. DE MAN (1), C. DUA (1), S. HENS (1), S. NULLENS (1), A. SMET (1), S. MALHOTRA (1), P. JORENS (2), G. HUBENS (2), B. DE WINTER (1) / [1] UAntwerpen, [2] UZ Antwerpen – UAntwerpen

9:45 B 16 Invited Lecture: The touchy business of GI mucosal mechanosensitivity.

A. BEYDER / Rochester, USA

10:30 Coffee Break

SESSION 2

CHAIRS: J.-P. Timmermans (UAntwerpen), P. Vanden Berghe (KULeuven)

11:00 Invited Lecture: Enteric neurons and mechanosensitivity: MEN at work.

G. MAZZUOLI-WEBER / Hannover, Germany

11:45 B 04 Mrgprc11 is expressed in murine viscerosensory spinal neurons: an immunohistochemical and retrograde tracing study.

S. VAN REMOORTEL, J. DE MAN, B. DE WINTER, R. BUCKINX, J.-P. Timmermans / UAntwerpen

12:00 B 05 Live calcium imaging reveals neuronal circuitry differences in the mouse colon.

Z.L. LI (1), M.M. HAO (2), W. BOESMANS (1), P. VANDEN BERGHE (1) / [1] KULeuven, [2] University of Melbourne, Australia

[RETHINK PBC]

The GLOBE score:
ALP, bilirubin, age,
albumin and platelet count
are markers of disease
progression in PBC

Inadequately treated primary biliary cholangitis (PBC) can lead to liver transplantation or death^{1,2}



Up to 40% of patients taking ursodeoxycholic acid (UDCA), may not be achieving an adequate response to treatment, as indicated by a GLOBE score of $>0,30$. So it is important to monitor your patients regularly³



Alkaline phosphatase (ALP), bilirubin, age, albumin and platelet count are markers of both disease progression and response to therapy.³ A GLOBE score of $>0,30$ in PBC patients is associated with significantly shorter times of transplant-free survival than matched healthy individuals ($P < 0,0001$).³



EASL recommends checking your patients' response to therapy one year after starting therapy

Check your patient's GLOBE score at www.globalpbc.com/globe

References: 1. Poupon R. Primary biliary cirrhosis: A 2010 update. *J Hepatol* 2010;**52**:745-58; 2. Corpechot C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. *Hepatology* 2008;**48**:871-7; 3. Lammers WJ, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. *Gastroenterology* 2015;**149**:1804-12; 4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. *J Hepatol* 2017;**67**(1):145-172.

Intercept 

12:15 B 06 Upregulation of mast cell related genes in irritable bowel syndrome.

J. AGUILERA-LIZARRAGA (1), D. BALEMANS (1), M. FLORENS (1), E. PERNA (1), L. DECRAECKER (1), S. THEOFANOUS (1), P. JAIN (1), A. DENADAI-SOUZA (1), D. LAMBRECHTS (2), M. WOUTERS (1), G. BOECKXSTAENS (1) / [1] KULeuven, [2] VIB Leuven

12:30 Lunch

SESSION 3

CHAIRS: R. Lefebvre (UGent), W. Boesmans (KULeuven)

13:30 Invited Lecture: Lipids and irritable bowel syndrome – an (un)likely connection.

J. FICHNA / University of Lodz, Poland

14:15 B 07 Food antigen-specific sensitization of nociceptive nerves as an underlying mechanism of visceral pain in IBS.

J. AGUILERA-LIZARRAGA (1), D. BALEMANS (1), C. LOPEZ-LOPEZ (2), J. JARAMILLO-POLANCO (2), E. PERNA (1), S. THEOFANOUS (1), M. FLORENS (1), L. DECRAECKER (1), P. JAIN (1), A. DENADAI-SOUZA (1), C. BREYNAERT (3), S. VANNER (2), D. REED (2), M. WOUTERS (1), G. BOECKXSTAENS (1) / [1] KULeuven, [2] Queen's Universtij, Canada, [3] UZ Leuven

14:30 B 08 Double-blind randomized placebo-controlled trial of a probiotic combination ProbioTer in irritable bowel syndrome.

F. MOKADDEM (1), F. FONTEYN (2), I. DIEDDEREN (2), B. BASTENS (3), J. DEFLANDRE (4), P. THONART (2), E. LOUIS (5) / [1] Cliniques Sud Luxembourg, Arlon, [2] Lacto Research SPRL, [3] CHC, Liège, [4] CHR Citadelle, Liège, [5] CHU Liège

14:45 B 09 Prospective study evaluating predisposing factors and immune-mediated mechanisms underlying post-infectious IBS.

M. FLORENS (1), S. VAN WANROOY (1), W. PEETERMANS (2), M. WOUTERS (1), W. VANBRABANT (2), J. DOOLEY (1), A. LISTON (1), G. BOECKXSTAENS (1) / [1] KULeuven, [2] UZ Leuven

15:00 B 10 Long term adherence and effects of low FODMAP diet in patients with IBS.

L. GOOSSENS (1), A. WEYNANTS (1), M. GENETELLO (2), D. DE LOOZE (2), M. VAN WINCKEL (2) / [1] UGent, [2] UZ Gent

15:30 Coffee Break

SESSION 4

CHAIRS: I. Depoortere (KULeuven), J.-M. Vanderwinden (ULB Brussels)

16:15 B 12 **The circadian clock regulates diurnal rhythmicity of microbial short-chain fatty acid production and their rhythmic effects on colon contractility.**

SEGERS, L. DESMET, T. THYS, K. VERBEKE, J. TACK, I. DEPOORTERE / KULeuven

16:30 B 13 **Influence of the slow-release H₂S donor GYY4137 and the H₂S-releasing naproxen derivative ATB-346 on postoperative ileus.**

J. VAN DINGENEN, R. LEFEBVRE / UGent

16:45 B 14 **Effect of resolvin D1, D2 and E1 on histamine-induced sensitization of TRPV1.**

E. PERNA, M. FLORENS, J. AGUILERA, S. THEOFANOUS, L. DECRAECKER, M. WOUTERS, G. BOECKXSTAENS / KULeuven

17:00 B 15 **In toto three-dimensional microscopical imaging of the intestinal wall: comparison of eight clearing protocols.**

G. BOSSOLANI (1), J. DETREZ (2), J. ZANONI (1), W. DE VOS (2), R. BUCKINX (2), J.-P. TIMMERMANS (2) / [1] State University of Maringa, Brazil, [2] UAntwerpen

17:15 **Concluding remarks**

I. DEPOORTERE / KULeuven

Case Reports

SESSION 2: Interactive Case Report

CHAIRS: P. Caenepeel (ZOL, Genk), C. Van Kemseke (CHU Liège)

09:00 C 09 Endoscopic submucosal dissection of a granular tumour of the oesophagus: a Case Report.

C. DE VLOO (1), F. MAROLLEAU (2), J. DEWYSELAERE (2), L. DESOMER (2), E. STEENKISTE (2), D. DE WULF (2)
[1] UZ Leuven, [2] AZ Delta, Roeselare

09:20 C 10 Two rare conditions at the same time after gastric bypass in a young female.

D. DOOREMONT / AZ Sint-Elisabeth, Zottegem

09:40 C 11 A case of severe enteropathy.

P. HENRY, H. DANO, H. PIESSEVAUX, A. JOURET-MOURIN / UCL Saint-Luc

10:00 Coffee Break

CHAIRS: P. Caenepeel (ZOL, Genk), C. Van Kemseke (CHU Liège)

10:20 C 12 Probiotics in a critically ill malnourished patient: to do or not to do.

M. FIGUEIREDO, T. SERSTÉ, M. VAN GOSSUM / CHU Saint-Pierre

10:40 C 13 An unusual cause of gastrojejunal anastomotic stenosis after Roux-en-gastric bypass.

Z. ISSA (1), F. CORBISIER (1), P. DELRÉE (2), P. WARZÉE (1)/[1] GHDC, Charleroi, [2] IPG, Charleroi

11:00 C 14 Adenocarcinoma of the gastroesophageal junction after bariatric surgery: Two cases reports.

M. VAN GOSSUM, M. FIGUEIREDO, E. BRAUNS, P. EISENDRATH / CHU Saint-Pierre

11:20 C 15 Endoluminal vacuum therapy for the treatment of esophageal anastomotic leaks.

M. STRUYVE, H. VAN VEER, L. DEYPERE, P. NAFTEUX, P. ROELANDT / UZ Leuven

11:40 C 16 Unusual yellow to orange colonic mucosal appearance: what could that be?

M. STRUYVE (1), M. FERRANTE (1), W. MEERSSEMAN (1), L. VAN OVERBEKE (2), D. CASSIMAN (1)/[1] UZ Leuven, [2] AZ Sint-Maarten, Mechelen

11:50 Q & A

12:00 End of the Session

Moderators: L. van Grunsven (UZ Leuven) / I. Leclercq (UCL Saint-Luc, Brussels)

- 12:15 A 35 CD4+ RORyt+ T cells, CD4+ T-bet+, CD4+ CD25+ Foxp3+ T cells and CD8+ T cells are differentially altered in liver and adipose tissue of mice fed a high-fat high-fructose diet in a time-dependent manner.**
M. VAN HERCK (1), L. VONGHIA (2), P. MICHIENSEN (2), C. BRIDTS (3), D. EBO (1), J. DE MAN (1), B. DE WINTER (1), S. FRANQCQUE (2) / [1] UAntwerpen, [2] UZ Antwerpen
- 12:20 I 25 Epidemiology of Clostridium difficile infections in IBD over two decades.**
 A. MOENS (1), B. VERSTOCKT (1), K. MACHIELS (2), P. BOSSUYT (3), A. VERDONCK (1), K. LAGROU (1), S. VERMEIRE (1), M. FERRANTE (1) / [1] UZ Leuven, [2] KU Leuven, [3] Imeldaziekenhuis, Bonheiden
C. CAENEPEEL (1)
- 12:25 A 28 Under constant injury ductular-derived hepatocytes clonally grow as robust carcinogenesis-resistant population.**
R. MANCO (1), L. CLERBAUX (1), M. BOU NADER (2), C. SEMPOUX (3), C. DESDOUETS (2), Y. HORMSANS (1), I. LECLERCQ (1) / [1] UCL, Brussels, [2] Université Paris-René Descartes, France, [3] CHUV, Lausanne, Switzerland
- 12:30 A 34 Cu isotope ratio shifts in common bile duct ligated mice and correlates with the degree of cholestatic-induced liver disease.**
S. VAN CAMPENHOUT (1), M. COSTAS-RODRIGUEZ (2), A. HASTUTI (2), S. RAEVENS (1), A. GEERTS (1), X. VERHELST (1), F. VANHAECKE (2), H. VAN VLIERBERGHE (1), L. DEVISSCHER (1) / [1] UZ Gent, [2] UGent
- 12:35 I 34 The interaction between intestinal permeability disturbances and inflammation in a chronic colitis mouse model, studied over time.**
H. VAN SPAENDONK, J. DE MAN, S. FRANQCQUE, H. DE SCHEPPER, B. DE WINTER / UZ Antwerpen
- 12:40 O 08 Identification of new pathways driving muscle atrophy and biomarkers reflecting muscle atrophy in cancer cachexia.**
G. PAULISSEN (1), R. DE WALQUE (2), L. BINDELS (3), N. DELZENNE (3), J. THISSEN (3), E. DE PAUW (1), M. MEUWIS (4), E. LOUIS (4) / [1] GIGA-R, ULg, [2] UCL, Brussels, [3] KULeuven, [4] CHU de Liège
- 12:45 I 22 Potential diagnostic biomarkers of Ulcerative colitis-associated colorectal dysplasia.**
A. MERLI (1), C. MASSOT (1), N. BLÉTARD (2), F. QUESADA CALVO (1), D. BAIWIR (1), G. MAZZUCHELLI (1), N. SMARGIASSO (1), L. SERVAIS (1), C. OURY (1), M. DE PAUW-GILLET (1), E. DE PAUW (1), C. COIMBRA MARQUES (2), A. COLARD (3), A. VIJVERMAN (4), P. DELVENNE (2), M. MEUWIS (1), E. LOUIS (1) / [1] ULg, [2] CHU de Liège, [3] CHC de Liège, [4] CHR Citadelle de Liège
- 12:50 I 27 Serum proteomic profiling in Crohn's disease patients undergoing ileocolonic resection reveals discriminative inflammatory markers for endoscopic recurrence.**
K. MACHIELS, M. DE BRUYN, S. VERSTOCKT, B. VERSTOCKT, G. VAN ASSCHE, A. WOLTHUIS, A. D'HOORE, M. FERRANTE, S. VERMEIRE / UZ Leuven
- 12:55 Q & A**

SESSION 3: JAK inhibition**CHAIRS:** Pieter Dewint (Gent), Jean-François Rahier (Namur)**13:15** **Satellite Symposium Takeda**

Invited speaker: Shomron Ben-Horin, Tel-Aviv, Israel

14:00 **Invited Lecture: JAK inhibitors: can they replace biologicals?**

Charlie Lees / Edinburgh, UK

14:25 **I09** **Thiopurine monotherapy still has a place in the treatment of patients with mild-to- moderate Crohn's disease in the biological era.**

L. BOETS, B. VERSTOCKT, G. VAN ASSCHE, S. VERMEIRE, M. FERRANTE / UZ Leuven

14:35 **I 10** **Ustekinumab induces clinical and biological remission in biologic refractory Crohn's disease patients.**

C. LIEFFERINCKX (1), B. VERSTOCKT (2), A. GILS (3), M. NOMAN (2), C. VAN KEMSEKE (4), E. MACKEN (5), M. DE VOS (6), W. VAN MOERKERCKE (7), J. RAHIER (8), P. BOSSUYT (9), J. DUTRÉ (10), E. HUMBLET (11), D. STAESSEN (12), H. PEETERS (13), P. VAN HOOTEGEM (14), E. LOUIS (4), D. FRANCHIMONT (1), F. BAERT (14), S. VERMEIRE (2) / [1] ULB Erasme Brussels, [2] UZ Leuven, [3] KULeuven, [4] CHU Sart-Tilman, ULiège, [5] UZAntwerpen, [6] UZ Gent, [7] AZ Groeninge, Kortrijk, [8] CHU Mont-Godinne, UCL Saint-Luc, Brussels [9] Imelda Ziekenhuis, [10] ZNAntwerpen, [11] ZOL - Campus Sint-Jan, [12] GZA Sint-Vincentius Ziekenhuis, Antwerpen, [13] AZ Sint- Lucas, Brugge, [14] AZ Delta, Roeselare

14:45 **I 11** **Risk of cmv reactivation in uc patients with previous history of cmv infection following infliximab or vedolizumab treatments.**

C. HOMMEL (1), X. ROBLIN (2), L. BRICHET (2), B. BIHIN (1), S. PILLET (2), J. RAHIER (1) / [1] CHU UCL Namur, Yvoir, [2] University Hospital Saint Etienne, France

14:55 **I 12** **Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohn's disease.**

B. VERSTOCKT (1), M. NOMAN (1), I. AERDEN (1), M. PEETERS (2), E. BROUWERS (2), V. BALLEET (1), L. VANDERSMISSEN (2), G. VAN ASSCHE (1), A. GILS (2), S. VERMEIRE (1), M. FERRANTE (1) / [1] UZ. Leuven, [2] KULeuven

15:05 **Invited Lecture: JAK inhibitors: is the increased risk of viral infections a real threat?**

Marc Van Ranst / Leuven

15:30 **Coffee Break**

XXXth edition • 21-23 February 2018 • Hilton Hotel • Antwerp

Takeda Satellite symposium

February 22nd from 13h15 till 14h00

PK/PD for guiding therapy with vedolizumab: lessons from clinical experience




**Room
LIJN**

Prof. Dr. Shomron Ben-Horin

Associate Professor and Director of
the inflammatory bowel disease (IBD) service
at Sheba Medical Center, Tel-Aviv University, Israel.

SESSION 4: Positioning of medical therapies in IBD**CHAIRS:** Catherine Reenaers (Liège), Filip Baert (Roeselare)**16:00 I13 Effectiveness and persistence of vedolizumab in patients with inflammatory bowel disease: Results from the Belgian REal-Life study with VEdolizumab (Be-RELIVE).**

C. REENAERS (1), A. CREMER (2), O. DEWIT (3), B. DE VROEY (4), W. VAN MOERKERCKE (5), P. BOSSUYT (6), V. MULS (7), J. IMSCHOOT (8), S. BLOCK (8), A. HANTSON (8), V. PHILIPPE (9) / [1] ULiège, [2] ULB Erasme Brussels, [3] UCL Saint-Luc, Brussels, [4] Centre Hospitalier de Jolimont-Lobbes, La Louvière, [5] AZ Groeninge, Kortrijk, [6] Imelda Hospital, Bonheiden, [7] CHU Saint-Pierre, Brussels, [8] Takeda Belgium, [9] AZ Sint-Lucas, Brugge

16:10 I14 Vedolizumab trough levels during induction in ibd patients: a longitudinal observational retrospective study.

C. LIEFFERINCKX (1), A. CREMER (1), C. MINSART (1), A. GILS (2), L. AMININEJAD (1), V. TAFCIU (3), E. QUERTINMONT (3), J. DEVIÈRE (1), A. VAN GOSSUM (1), D. FRANCHIMONT (1) / [1] ULB Erasme, Brussels, [2] KULeuven, [3] ULB, Brussels

16:20 I15 Vedolizumab can induce clinical remission in patients with chronic antibioticrefractory pouchitis: a retrospective single centre experience.

C. CLAEYS, B. VERSTOCKT, G. VAN ASSCHE, A. D'HOORE, A. WOLTHUIS, S. VERMEIRE, M. FERRANTE / UZ Leuven

16:30 I16 Outcome of pregnancies in vedolizumab treated female IBD patients.

A. MOENS (1), K. VAN HOEVE (1), E. HUMBLET (2), J. RAHIER (3), P. BOSSUYT (4), S. DEWIT (5), D. FRANCHIMONT (6), E. MACKEN (7), J. NIJS (8), A. POSEN (9), A. VAN HOOTEGEM (10), W. VAN MOERKERCKE (11), S. VERMEIRE (1), M. FERRANTE (1) / [1] UZ Leuven, [2] ZOL, Genk, [3] CHU UCL Namur, Yvoir, [4] Imelda Ziekenhuis, [5] Mariaziekenhuis Noord-Limburg, Overpelt, [6] ULB Erasme, Brussels, [7] UZAntwerpen, [8] Sint-Trudo ziekenhuis, Sint-Truiden, [9] AZ Vesalius Tongeren, [10] AZ Klina, [11] AZ Groeninge, Kortrijk

16:40 Invited Lecture: Initiating biological therapies in IBD: do I have to use other drugs for CD than for UC?

Shomron Ben-Horin / Tel Aviv, Israel

E - POSTERS

13:00 SESSION 1: Guided e-Poster Tour
CHAIRS: T. Moreels (UCL Saint-Luc, Brussels),
A. Lemmers (ULB Erasme, Brussels),
X. Dekoninck (Clinique St-Pierre Ottignies), D. Blero (CHU Charleroi)

G 09 Intraductal cholangioscopy and pancreatoscopy indications and results.

A. TAHA, R. GARCES DURAN, T. MOREELS, R. YEUNG, T. AOUATTAH, M. KOMUTA, H. PIESSEVAUX, P. DEPREZ / UCL Saint-Luc Brussels

G 10 Transanal endolaparoscopy: an innovative treatment of Colorectal anastomotic leakages.

G. DAPRI, V. MULS, R. NTOUNDA, M. VAN GOSSUM, M. BUSET, P. EISENDRATH / CHU Saint-Pierre, Brussels

G 11 @ERCP in patients with Roux-en-Y altered anatomy and intact Vater's papilla.

E. AKPOKAVIE, A. SLIMANI, P. DEPREZ, H. PIESSEVAUX, T. MOREELS / UCL Saint-Luc, Brussels

G 12 Endoscopic treatment of postoperative fistulas in the upper gastrointestinal tract.

T. ROOSVELT, B. NAVEZ, M. THOMA, Y. DESWYSEN, P. DEPREZ, H. PIESSEVAUX, T. MOREELS / UCL Saint-Luc, Brussels

G 13 Is Lugol necessary for endoscopic resection of squamous cell neoplasia of the esophagus?

A. FERREIRA (1), C. MOURADIDES (2), E. ROBLES (2), R. YEUNG (2), R. DURAN (2), C. SNAUWAERT (2), A. JOURET-MOURIN (2), H. PIESSEVAUX (2), P. DEPREZ (2) / [1] Hospital Beatriz Ângelo, Loures, Portugal, [2] UCL Saint-Luc, Brussels

G 14 Management of leaks after bariatric surgery by double-pigtail stent insertion. A single-center experience.

G. BURNET, Y. HOEBEKE, F. CORBISIER, P. WARZÉE / GHDC, Charleroi

G 15 Endoscopic management of biliary leaks : a systematic review.

K. VLAEMYNCK, P. HINDRYCKX / UZ Gent

G 16 EUS-guided biliary drainage and EUS-guided rendezvous technique when ERCP fails. A single center cohort database.

D. DE WULF, L. DESOMER, F. BAERT / AZ Delta, Roeselare

G 17 Persistent pain after colonic endoscopic mucosal resection: Predictors, a management algorithm and outcomes.

L. DESOMER (1), D. TATE (2), H. AWADIE (2), L. PILLAY (2), G. AHLENSTIEL (2), M. BOURKE (2) / [1] AZ Delta, Roeselare, [2] Westmead Hospital, Sydney, Australia

G 18 Intraductal ablation by radiofrequency probe or cystostome during Endoscopic ampullectomy may reduce the long-term recurrence rate.

E. PEREZ-CUADRADO, H. PIESSEVAUX, T. MOREELS, A. JOURET-MOURIN, P. DEPREZ / UCL Saint-Luc, Brussels

SESSION 2: Oral presentations and Invited Lectures.

CHAIRS: T. Moreels (UCL Saint-Luc, Brussels), C. Snauwaert (AZ Brugge)

14:00 G01 Automated digital calculation of endoscopic inflammation in ulcerative colitis: results of the red density study.

P. BOSSUYT (1), H. NAKASE (2), S. VERMEIRE (3), H. WILLEKENS (3), Y. IKEMOTO (4), T. MAKINO (4), R. BISSCHOPS (4) / [1] Imelda Hospital, Bonheiden, [2] Sapporo Medical University, Japan, [3] UZ Leuven, [4] Pentax Medical, Tokyo, Japan

14:15 G02 Endobiliary radiofrequency ablation in patients with inoperable biliopancreatic tumors complicated with obstructive jaundice: the IGNITE-1 trial.

W. LALEMAN, S. VAN DER MERWE, L. VERBEKE, H. VAN MALENSTEIN, R. AERTS, H. PRENEN, E. VAN CUTSEM, C. VERSLYPE / UZ Leuven

14:30 G03 Simple endoscopic treatment of adenoma recurrence after wide field endoscopic mucosal resection is effective: A prospective study of 1558 lesions with long term follow up.

D. TATE (1), L. DESOMER (2), H. AWADIE (1), M. SIDHU (1), N. BURGESS (1), K. GOODRICK (1), M. BOURKE (1) / [1] Westmead Hospital, Sydney, Australia, [2] AZ Delta, Roeselare

14:45 G04 Self-sizing radiofrequency ablation balloon for eradication of Barrett's esophagus: results of an international multicenter randomized trial comparing three different treatment regimens.

K. BELGHAZI (1), R. POUW (1), A. KOCH (2), B. WEUSTEN (3), E. SCHOON (4), W. CURVERS (4), A. GOTINK (2), R. HAIDRY (5), O. PECH (6), J. BERGMAN (1), R. BISSCHOPS (7) / [1] Academic Medical Center, Amsterdam, Netherlands, [2] Erasmus Medical Center, Rotterdam, Netherlands, [3] St. Antonius Hospital, Nieuwegein, Netherlands, [4] Catharina Hospital, Eindhoven, Netherlands, [5] University College London Hospitals, UK, [6] St. John of God Hospital, Regensburg, Germany, [7] UZ Leuven

15:00 Invited Lecture: ESGE quality indicators for lower GI endoscopy.

Marek Bugajski / Warsaw, Poland

15:30 Coffee break.

Anticoagulation & GE : **Where are we after 5 years** **of NOAC ?**

Interactive dialogue between
2 specialists and the audience



Satellite Symposium

Thursday February 22, 2018

Timing : 17:20 - 18:05

XXXth BWGE - 2018

Hilton Hotel

Antwerpen

Moderator **Prof. Daniel Blero**, CHU Charleroi
President of BSGIE

Speakers **Prof. Pierre Deprez**, UCL - Gastroenterology
Prof. Kristin Jochmans, UZ Brussels - Hematology

SPC and full Prescribing Information will be available at BMS Pfizer Alliance Exhibition Booth
GE: Gastroenterology

NOACs: non-vitamin K antagonist oral anticoagulants



This Satellite Symposium is fully organised and funded by:



Date of preparation: December 2017 - 432BE17PR09571-171252

SESSION 3: Oral presentations and Invited Lectures.

CHAIRS: M. Aerts (VUB Jette), A. Vijverman (CHC Liège)

16:00 G 05 An international survey of colorectal polypectomy practice demonstrates encouraging adherence to published guidance.

D. TATE (1), L. DESOMER (2), N. BURGESS (1), H. AWADIE (1), S. HEITMAN (3), N. FORBES (3), D. DE LOOZE (4), J. ANDERSON (5), D. REX (6), M. BOURKE (1) / [1] Westmead Hospital, Sydney, Australia, [2] AZ Delta, Roeselare, [3] Cumming School of Medicine, University of Calgary, Canada, [4] UZ Gent, [5] Cheltenham General Hospital, UK, [6] Indiana University School of Medicine, Bloomington, USA

16:12 G 06 Higher mean boston bowel preparation scale scores with 1l pegbased ner1006 versus 2l peg + ascorbate: post hoc analysis of a randomised phase 3 clinical trial.

R. BISSCHOPS (1), B. BASTENS (2), A. HOLVOET (3), R. HENRAR (4), M. DE VOS (5) / [1] UZ Leuven, [2] CHC Clinique Saint-Joseph, Liège, [3] AZ Sint-Lucas Brugge, [4] Norgine NV, Leuven, [5] UZ Gent

16:24 G 07 Launching an Endoscopic Submucosal Dissection (ESD) program in a European academic hospital: review of the first 28 months of experience.

A. LEMMERS, V. HUBERTY, C. MUSALA, A. BUCALAU, P. DEMETTER, L. VERSET, J. VAN LAETHEM, A. BUGGENHOUT, I. EL NAKADI, J. DEVIÈRE / ULB Erasme Brussels

16:36 G 08 EUS today and tomorrow: what are we doing today in real practice in different countries and where are we going?: a Belgian survey.

L. VANDEPUTTE (1), P. DEPREZ (2) / [1] AZ Sint-Jan Brugge-Oostende, [2] UCL Saint-Luc Brussels

16:50 Invited Lecture: Optical diagnosis: how do I do it?

E. Dekker / Amsterdam, Netherlands

17:20 Satellite Symposium BMS/PFIZER Alliance

Speakers: P. Deprez (UCL Saint-Luc, Brussels).
K. Jachmans (UZ Brussel).

THIS YEAR, the **Belgian week** organizes once again a practical, hands on session in ultrasound on **Wednesday** and **Thursday** afternoon.

Thursday afternoon the session will focus on **ultrasound in bowel pathology**. For this course, we aim to gastroenterologists with interest in bowel disorders and the role of abdominal ultrasound.

After a short introduction, participants will be instructed on simulators from the **Hannover University**. The machines that will be used for the course are simulators demonstrating real life images of abdominal pathology. During the session we will focus on inflammatory bowel disorders.



XXXth Anniversary
Dinner & Party



Thursday February 22nd
BWGE XXXth Anniversary

VENUE

The top floor of the MAS Museum
Hanzestedenplaats, 5 – 2000 Antwerpen

Time: 7:30 pm XXXth Anniversary Celebration & Aperitive
8:30 pm Dinner & Party

Bus transfers: 7:00 pm Departure from the Hilton Hotel
11:00 pm – 12:00 pm – 1:00 am
Departures from the MAS Museum

Registration: 35€ for registered participants 80€ for an accompanying person.
A lot of memories from all these years, make sure to reserve your place !

Moderators: Manon van der Vlugt (Amsterdam, Netherland), Marek Bugaski (Warsaw, Poland) & Daniel Blero (Charleroi, Belgium)

LOWER GASTRO-INTESTINAL ENDOSCOPY: ARE WE DOING WELL? HOW CAN WE DO BETTER?

Live endoscopy from ULB Erasme, Brussels with demonstration and discussion about implementation of key indicators of performance in colonoscopy.

Different aspects of colonoscopy will be considered:

- Application of diagnosis techniques,
- Evaluation and treatment of common clinical situations (screening colonoscopy,
- IBD evaluation and description, polyps assessment and description, polypectomy techniques, tattooing policy...), adequate reporting,
- Evaluation of complication rate,



BWGE 2018 AWARDS CEREMONY

BWGE 2018 Grants:

BWGE 2018 Research Grant

Laurens Ceulemans, KUL

Villin-1 is a novel serological biomarker for intestinal ischemia and reperfusion injury in rats and humans

Promotor Pr. J. Pirenne

Abdominal Transplantation Surgery, University Hospitals Leuven, Belgium; Microbiology and Immunology, KULeuven, Belgium

BWGE 2018 Research Grant

Tanguy Demaret, UCL

Study of extracellular vesicles released by liver and umbilical cord mesenchymal stem cells to restore peroxisome biogenesis in Zellweger spectrum disorders

Promotor Pr E. Sokal

Lab Paediatric hepatology and cell therapy lab (PEDI)
Université Catholique de Louvain
Brussels

BWGE 2018 Research Grant

Astrid Vandierendock, UGhent

Characterisation of the UPR and DUB (deubiquitinases) signature in the CSCs (cancer stem cells) of human primary HCCs

UGhent (H. Van Vlierberghe) & KUL (T. Roskams)

DUB (deubiquitinases)
CSCs (cancer stem cells)

ACTA Gastroenterologica Grant

Lisbeth Vandenabeele

The predictive value of negative capsule endoscopy for the indication of Obscure Gastrointestinal Bleeding: no reassurance in the long term.

Cedric Van de Bruaene, Pieter Hindryckx, Christophe Snauwaert, Diederik Dooremont, Bruno Vanduyfhuys, Martine De Vos, Danny De Looze.

BWGE 2018 Prizes:

Best Clinical Poster

Best Basic Poster

BIRD Prize

BeSPGHAN Prize

BGDO Prize



SESSION 1: Infectious anorectal diseases and selected abstracts**CHAIRS:** C. Van Kemseke (U Liège), H. De Schepper (UZ Antwerpen)**9:00 M 01 Dynamic transrectal ultrasound versus MR defecography in patients with constipation.**

K. VAN MALDEREN (1), M. SOMERS (2), M. SPINHOVEN (3), H. DE SCHEPPER (2) / [1] U Antwerpen, Gastroenterology & Hepatology, [2] UZ Antwerpen, Gastroenterology & Hepatology, [3] UZ Antwerp, Radiology

9:15 M 02 Injection of botulinum toxin in the treatment of anal fissure can be performed safely in patients actively receiving chemotherapy.

P. ROELANDT (1), G. COREMANS (1), J. WYNDAELE (1) / [1] UZ Leuven, Gastroenterology and Hepatology

9:30 Invited Lecture: Sexually transmitted diseases of the anorectum.

D. DE LOOZE / UZ Gent, Gastroenterology and coloproctology

10:00 M 03 Hemorrhoidal disease in Belgian clinical practice: Results of the CHORUS study (Chronic venous and HemORrhoidal diseases evaluation and Scientific research).

H. DE SCHEPPER (1), M. SOMERS (1), D. DE LOOZE (2) / [1] UZ Antwerpen, Gastroenterology & Hepatology, [2] UZ Gent, Gastroenterology

10:15 M 04 Thunderbeat®-assisted haemorrhoidectomy in symptomatic prolapsing haemorrhoids. A pilot trial.

L. HEYERICK (1), D. VAN DE PUTTE (2), M. DE VISSCHERE (2), P. PATTYN (2), H. VAN VLIERBERGHE (1), D. DE LOOZE (1) / [1] UZ Gent, Department of Gastroenterology, [2] UZ Gent, Digestive surgery.

10:30 Coffee break**SESSION 2****CHAIRS:** P. Roelandt (UZ Leuven), MA Denis (UCL Brussels)**11:00 M 05 Curious intra-rectal "laterally spreading tumor" in immunosuppressed patient with ulcerative colitis.**

S. VIEUJEAN (1), P. LATOUR (1), C. COIMBRA MARQUES (2), E. LOUIS (1), C. VAN KEMSEKE (1) / [1] CHU Sart Tilman, Liège, Gastroenterology, [2] CHU Sart Tilman, Liège, Abdominal surgery

11:10 Invited Lecture: Manifestations of Human Papilloma Virus infection at the anal canal – anal intraepithelial neoplasia – early detection and prevention.

O. RICHEL / Dep. of Infectious Diseases, Academic Medical Center, Amsterdam

11:40 What you've always wanted to know but never dared to ask: tips and tricks for frequent and unusual proctology cases (interactive session)

MA DENIS / UCL Brussels and P ROELANDT / UZ Leuven

8:00 Breakfast Satellite Symposium LILLY

Speakers: Prof. M. Van den Eynde, Prof. Van Buistem, Prof S.L Van Laethem, Prof. M Peeters

SESSION 1**CHAIRS:**

Alain Hendlisz (ULB Bordet, Brussels), Karen Geboes (UZ Gent)

8:30 O 01 Prognostic value of tumor location in colorectal carcinoma: a Belgian population based study.

K. JANSSENS (1), N. BOECKX (2), K. OP DE BEECK (2), E. FRANSEN (1), F. CALAY (3), N. VAN DAMME (3), M. PEETERS (5) / [1] UAntwerp, [2] Center for Oncological Research (CORE), Edegem, [3] Belgian Cancer Registry, Brussel, [5] UZAntwerpen

8:42 O 06 A novel post-surgical prognostic system for colorectal liver metastases treated by preoperative systemic treatment, using tumoral and non tumoral pathological changes, RAS mutation and Immunoscore.

P. BALDIN (1), M. VAN DEN EYNDE (1), B. MLECNIK (2), G. BINDEA (2), G. BENIUGA (4), J. CARRASCO (5), C. HUBERT (1), B. NAVEZ (1), G. PAIRET (6), A. JOURET-MOURIN (1), G. GALON (2), M. KOMUTA (1) / [1] UCL Saint-Luc Brussels, [2] INSERM UMRS1138 Laboratory of Integrative Cancer Immunology, Paris, France, [4] IPG, Charleroi, [5] GHDC, Charleroi, [6] Centre Hospitalier de Jolimont-Lobbes, La Louvière

8:54 O 03 Preoperative gemcitabine-nab-paclitaxel (G-NP) for (borderline) resectable (BLR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC): a feasibility and proof of concept study.

L. MANS (1), I. BORBATH (2), M. BALI (1), G. VERSET (1), A. DEMOLS (1), F. PULEO (1), L. ANNET (2), M. KOMUTA (2), P. DEMETTER (1), J. VAN LAETHEM (1), R. MARECHAL (1) / [1] ULB Erasme Brussels, [2] UCL Saint-Luc Brussels

9:06 O 04 Impact of introduction of an enhanced recovery pathway in esophageal cancer surgery: a prospective cohort study and propensity score matching analysis.

Y. MANDEVILLE, J. MOONS, A. RINGOET, L. DEPYPERE, W. COOSEMANS, H. VAN VEER, P. NAFTEUX / UZ Leuven

9:18 O 05 Long term oncological results and quality of life after HIPEC for carcinomatosis of colorectal origin.

S. BARBOIS, D. LEONARD, A. SOUCHET, C. REMUE, N. ABBES ORABI, R. BACHMANN, M. VAN DEN EYNDE (3), X. WITTEBOLE (4), E. COTTE (1), E. DANSE (5), A. JOURET MOURIN (6), A. DRAGEAN (5), G. LECLERCQ (7), A. KARTHEUSER (1) / UCL Saint-Luc Brussels



BGDO Session and Satellite Symposia during the Belgian Week of Gastroenterology

Friday 23 February 2018 - Hilton Antwerp - Meeting room TEUN

In collaboration with BGDO, Lilly organises a breakfast meeting during the Belgian week of Gastroenterology.

Optimizing sequential treatment in gastric cancer

Patient case and discussion

Case presenter: Prof. Marc Van den Eynde

Panel experts: Prof. Eric Van Cutsem | Prof. Jean-Luc Van Laethem | Prof. Marc Peeters

Leave on time to avoid the traffic jam and enjoy breakfast as from 7:45!

Looking forward to meeting you all on 23 February at the Hilton hotel.

PP-ON-BE-0020-JAN2018

This material is meant only for individuals allowed by law to prescribe or deliver medicines
Responsible publisher: ELB – Markiesstraat ¼ B, Rue du Marquis – 1000 Brussel – Bruxelles



BGDO Session and Satellite Symposia during the Belgian Week of Gastroenterology

Friday 23 February 2018 - Hilton Antwerp - Meeting room TEUN

In collaboration with BGDO, Servier organises a lunch meeting - lunchbox offered - during the Belgian week of Gastroenterology.

Redefining third line therapy in metastatic colorectal cancer

will be discussed using patient cases in an interactive way during 45 minutes.

Case presenters: Prof. Marc Peeters | Prof. Marc Van den Eynde

Chairmen: Prof. Eric Van Cutsem | Prof. Jean-Luc Van Laethem

Looking forward to meeting you all on 23 February at 12 o'clock
for a lunch meeting at the Hilton hotel.



9:30 O 02 Clinical Application and Potential Usefulness of Targeted Next-Generation Sequencing on Resected Pancreatic Ductal Adenocarcinoma.

F. PULEO (1), N. RÉMY (2), Y. BLUM (2), J. CROS (3), L. MARISA (2), P. DEMETTER (4), E. QUERTINMONT (4), M. SVRCEK (5), N. ELAROUCI (2), D. FRANCHIMONT (4), L. VERSET (4), J. DEVIÈRE (4), A. DE REYNIÈS (2), P. LAURENT-PUIG (6), J. BACHET (7), R. MARÉCHAL (4), J. VAN LAETHEM (4) / [1] ULB Bordet, Brussels, [2] Ligue Nationale Contre Le Cancer, Paris, France, [3] Hôpital Beaujon, Clichy, France, [4] ULB Erasme Brussels, [5] Hôpital Saint-Antoine, Paris, France, [6] Hôpital Européen Georges Pompidou, Paris, France, [7] Hôpital Pitié Salpêtrière, Paris, France

9:42 O 07 Inter-center heterogeneity in the quality of care for rectal adenocarcinoma in Belgium.

N. VAN DAMME (1), J. VANDEVEN (1), J. VERBEECK (1), J. XICLUNA (1), F. PENNINGCKX (2), A. KARTHEUSER (3), K. HAUSTERMANS (2), J. VAN LAETHEM (4), H. DE SCHUTTER (1), L. VAN EYCKEN (1) / [1] Belgian Cancer Registry, Brussel, [2] UZ Leuven, [3] UCL Saint-Luc Brussels, [4] ULB Erasme Brussels

9:54 Coffee break

SESSION 2: Highlights of the year
CHAIRS: Ivan Borbath (UCL Saint-Luc, Brussels), Marc Peeters (UZAntwerpen)

10:30 Upper GI cancers.

Marc Van Den Eynde / UCL Saint-Luc, Brussels

10:50 Hepato-Bilio-Pancreatic cancers.

Anne Demols / ULB Erasme Brussels

11:10 Colo-Rectal cancers.

Hans Prenen / UZ Leuven

11.30 Invited Lecture: "MSI testing in GI cancer: challenges and pitfalls"

Magali Svrcek / Hôpital Saint-Antoine, Paris, France

12:00 Satellite Symposium SERVIER.

Invited Speakers: Prof. M. VAN DEN EYNDE / Prof. E. VAN CUTSEM / Prof J-L. VAN LAETHEM
Prof. M. PEETERS

12:45 Lunch

12:00 **Lunch**

13:15 **Satellite Symposium BMS Oncology.**

Speakers : Prof. Pierre Coulie, UCL Brussels - Prof. Eric Van Cutsem, UZ Leuven

E - POSTERS

O08 Identification of new pathways driving muscle atrophy and biomarkers reflecting muscle atrophy in cancer cachexia.

G. PAULISSEN (1), R. DE WALQUE (2), L. BINDELS (3), N. DELZENNE (3), J. THISSEN (3), E. DE PAUW (1), M. MEUWIS (4), E. LOUIS (4) / [1] GIGA-R, ULiège, [2] UCL Saint-Luc, Brussels, [3] KULeuven, [4] CHU de Liège

O09 A Centre-based Study of Clinical and Molecular Characteristics of Post-Colonoscopy Colorectal Cancer.

C. SEVERI (1), G. VAN ROEY (2), J. JANSSENS (2) / [1] UZ Leuven, [2] AZ Turnhout

O10 Estimation of the future liver remnant function is a better tool to predict post-hepatectomy liver failure than platelet-based liver scores.

T. CHAPELLE , B. OP DE BEECK, A. DRIESSEN, G. ROEYEN, B. BRACKE, V. HARTMAN, I. HUYGHE, M. PEETERS, S. FRANQCUE, D. YSEBAERT / UZAntwerpen

O11 Estimation of the future liver remnant function supports parenchyma-saving hepatectomy combined with hepatic vein resection and reconstruction.

T. CHAPELLE, B. OP DE BEECK, G. ROEYEN, V. HARTMAN, B. BRACKE, D. YSEBAERT / UZAntwerpen

O12 Estimation of the future liver remnant function prior to hepatectomy may guide the indication for portal vein occlusion and avoid post-hepatectomy liver failure: a prospective interventional study.

T. CHAPELLE (1), B. OP DE BEECK (2), G. ROEYEN (2), B. BRACKE (2), V. HARTMAN (2), I. HUYGHE (2), S. FRANQCUE (2), P. MICHIELSEN (2), D. YSEBAERT (2) / [1] UAntwerpen, [2] UZAntwerpen

O13 Next- generation sequencing in cholangiocarcinoma: the quest for applicability and precision therapy!

A. BUCALAU, N. D'HAENE, P. DEMETTER, V. LUCIDI, G. VERSET, J. VAN LAETHEM, A. DEMOLS / ULB Erasme Brussels

Are we understanding immunotherapy? Challenges & Opportunities

> **Friday 23th of February:**
Satellite Symposium B-MS

> **Programme**

13.15 - 13.35 Understanding Immunoscience:
basics of Immunology
> *Prof. Pierre Coulie, UCL Brussels*

13.35 - 14.00 Future Trends in Immunotherapy
> *Prof. Eric Van Cutsem, UZ Leuven*



Bristol-Myers Squibb
Leading the Way in Immuno-Oncology



Immuno-Oncology

SESSION 1

CHAIRS: A. Hoorens (UZ Gent), P. Baldin (UCL Saint-Luc, Brussels)

- 9:00** **Introduction.**
A. Hoorens (UZ Gent)
-
- 9:05** **Invited Lecture : Non-HP gastritis.**
M. Rugge / Padova, Italy
-
- 9:40** **R 01** **An unusual gastric polyp.**
C. Van Paesschen, E. Macken, P. Pauwels , A. Snoeckx, M. Ruppert, A. Driessen / UZAntwerpen
-
- 9:50** **R 02** **Granular cytoplasmic expression of calretinin in Schwann cell hamartomas.**
L. Libbrecht (1), C. Hamoir (1), R. Sciot (2), A. Jouret-Mourin (1) / [1] UCL Saint-Luc, Brussels, [2]UZ Leuven
-
- 10:00** **Coffee Break**
-
- 10:45** **Invited Lecture: Non-IBD colitis.**
G. Cathomas / Liestal, Switzerland
-
- 11:20** **R 03** **Myxoid hepatocellular adenoma, a rare variant of liver cell adenoma, often clinically misdiagnosed as cavernous haemangioma.**
A.Hoorens, A. Candaele, M. Van der Linden, P. Smeets, C. Lecluyse, N. De Vos, R. Troisi, J. Van Dorpe /UZ Gent
-
- 11:30** **Invited Lecture: Auto-immune enteropathy.**
A. Driessen / UZAntwerpen
-
- 12:00** **Lunch**
-
- 14:00** **Introduction to the Brohée Prize.**
Ivan Borbath (UCL Saint-Luc Brussels)
-
- 14:05** **Brohée Prize Lecture: "Personalized medicine in GI oncology: myth or reality".**
S. Tejpar (KULeuven)

SESSION 2

CHAIRS: A. Driessen (UZAntwerpen), L. Verset (ULB Erasme Brussels)

14:30 **Invited Lecture: Neuroendocrine neoplasms of the GI tract: NET, NEC and MiNEN in the WHO 2017 classification.**

A.Hoorens / UZ Gent

15:00 **R 04** **Frequency of epidermal metaplasia in a retrospective monocentric series of mucosectomy for esophageal intraepithelial neoplasia and/or superficial squamous cell carcinoma.**

F. Al Zubi, H. Dano, H. Nasserddine, L. Libbrecht, P. Deprez, A. Jouret-Mourin / UCL Saint-Luc, Brussels

15:10 **R 05** **Endothelial indoleamine 2,3-dioxygenase expression in colorectal cancer: an earlymarker of disease relapse.**

A. Meireson (1), I. CHEvolet (1), E. Hulstaert (1), L. Ferdinande (1), P. Ost (1), K. Geboes (1), M. Deman (1), D. Van de Putte (1), L. Verset (2), V. Kruse (1), P. Demetter (2), L. Brochez (1) / [1] UZ Gent, [2] ULB Erasme, Brussels

15:20 **Coffee Break**

15:45 **Case presentations of “Non-HP-gastritis” and “Non-IBD colitis”.**

- S. Bigoundou-Nzamba (ULB Erasme Brussels)
- G. Broeckx (UZAntwerpen)
- A. Candaele (UZ Gent)
- A. De Roo (UZ Leuven)
- P. Henry (UCL Saint-Luc, Brussels)
- H. Van Beveren (UZ Gent)

16:45 **Invited Lecture: Disorders of the colon secondary to diagnostic procedures and treatments unrelated to drugs.**

L. Libbrecht / UCL Saint-Luc, Brussels

RESEARCH IN PAEDIATRICS: Practical use in daily practice
CHAIRS: Isabelle Paquot (CHC Liège), Myriam Van Winckel (UZ Gent)

- 13:30** **Diagnostic value of faecal calprotectine.**
 Els Van de Vijver / UZAntwerpen
- 13:50** **Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.**
 Karen Van Hoeve / UZ Leuven
- 14:10** **Human milk oligosaccharides in clinical studies.**
 Philippe Alliet / Jessa Ziekenhuis, Hasselt
- 14:30** **Gastric emptying in children in health and disease: an update for daily clinical practice.**
 Bruno Hauser / UZ Brussel
-
- 14:50** **Coffee break**
-

CHAIRS: Patrick Bontems (ULB, HUDERF, Brussels), Françoise Smets (UCL Saint-Luc, Brussels)

- 15:20** **K 01** **Infliximab trough levels after induction therapy are predictive for the outcome in paediatric patients with inflammatory bowel disease.**
 K. VAN HOEVE (1), I. HOFFMAN (1), E. DREESEN (2), M. FERRANTE (1), A. GILS (2), S. VERMEIRE (1) / [1] UZ Leuven, [2] KULeuven
- 15:30** **K 02** **Infliximab trough levels during maintenance are predictive for infliximab efficacy in paediatric patients with inflammatory bowel disease.**
 K. VAN HOEVE (1), I. HOFFMAN (1), E. DREESEN (2), M. FERRANTE (3), A. GILS (2), S. VERMEIRE (3) / [1] UZ Leuven, [2] KULeuven

- 15:40 K 03 Medical devices in EU claiming oropharyngeal or gastrointestinal barrier action: barrier products or hidden pharmacological agents?**
S. HUIJGHEBAERT (1), P. DE BRUYNE (2), K. ALLEGAERT (3), M. VAN WINCKEL (2) / [1] Pharmacist PhD, [2] UZ Gent, [3] KULeuven
- 15:50 Diagnostic and therapeutic challenges in pediatric chronic pancreatitis.**
Isabelle Scheers / UCL St Luc, Brussels
- 16:20 Immunological consequences of liver transplantation in children: making or breaking tolerance.**
Ruth De Bruyne / UZ Gent
- 16:40 General Assembly BeSPGHAN.**

E - POSTERS

- K04 Natural history of diarrhoea among under-five children in nalchity, Bangladesh.**
M. KHANAM / Centre for Injury Prevention and Research, Dhaka, Bangladesh
- K05 Medical devices marketed as medicines: safety and regulatory concerns in children.**
S. HUIJGHEBAERT (1), P. DE BRUYNE (2), M. VAN WINCKEL (3), K. ALLEGAERT (4) / [1] Independent researcher, Pharmacist, PhD, [2] UGent, [3] UZ Gent, [4] Erasmus MC, Rotterdam, Netherlands
- N01 Shifting paradigms in Intestinal Transplantation: from rescue therapy to standard of care for intestinal failure?**
E. CANOVAI, L. CEULEMANS, G. DE HERTOOGH, M. HIELE, M. SAINZ-BARIGA, D. MONBALIU, I. JOCHMANS, T. VANUYTSEL, J. PIRENNE / UZ Leuven

CHAIRS: I. Colle (Aalst & UZGent), G. Verset (ULB Erasme).

12:15 A 26 Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis.

A. MAROT (1), M. DUBOIS (2), E. TREPO (3), C. MORENO (3), P. DELTENRE (4) / [1] CHU UCL Namur, Yvoir, [2] CHUV, Lausanne, Switzerland, [3] ULB Erasme, Brussels, [4] UCL Saint-Luc Bouge, Namur

12:20 A 31 Alveolar echinococcosis is now endemic in southern Belgium.

A. CAMBIER (1), P. LEONARD (1), B. LOSSON (2), M. HAYETTE (1), J. GIOT (1), N. BLETARD (1), P. MEUNIER (1), R. HUSTINX (1), N. MEURISSE (1), J. DELWAIDE (1), P. HONORE (1), O. DETRY (1) / [1] CHU Liege, [2] ULiège

12:25 A 39 Loss-to-follow-up is an important problem in the diagnosis and follow-up of hepatitis C.

W. VERLINDEN (1), S. FRANQCUE (1), T. HOLVOET (2), S. VAN HEES (3), C. COTTIGNIE (3), V. WIJTVLIET (3), L. VONGHIA (1), P. MICHELSEN (1), T. VANWOLLEGHEM (1) / [1] UZAntwerpen [2] AZ Nikolaas, Sint-Niklaas, [3] UAntwerpen

12:30 Estimation of the future liver remnant function is a better tool to predict post-hepatectomy liver failure than platelet-based liver scores.

T. CHAPPELLE (1), B. OP DE BEECK (2), A. DRIESSEN (3), G. ROEYEN (4), B. BRACKE (4), V. HARTMAN, I. HUYGHE, M. PEETERS, S. FRANQCUE, D. YSEBAERT / UZAntwerpen

12:35 I 22 Potential diagnostic biomarkers of Ulcerative colitis-associated colorectal dysplasia.

A. MERLI (1), C. MASSOT (1), N. BLÉTARD (2), F. QUESADA CALVO (1), D. BAIWIR (1), G. MAZZUCHELLI (1), N. SMARGIASSO (1), L. SERVAIS (1), C. OURY (1), M. DE PAUW-GILLET (1), E. DE PAUW (1), C. COIMBRA MARQUES (2), A. COLARD (3), A. VIJVERMAN (4), P. DELVENNE (2), M. MEUWIS (1), E. LOUIS (1) / [1] ULg, [2] CHU de Liège, [3] CHC de Liège, [4] CHR Citadelle de Liège

12:40 G 09 Intraductal cholangioscopy and pancreatoscopy indications and results.

A. TAHA, R. GARCES DURAN, T. MOREELS, R. YEUNG, T. AOUATTAH, M. KOMUTA, H. PIESSEVAUX, P. DEPREZ / UCL Saint-Luc, Brussels

12:45 I 36 The clinical utility of a multi-marker serum test for assessment of ulcerations in infliximab treated patients with Crohn's disease.

M. DE BRUYN (1), T. BESSISSOW (2), V. KONDRAGUNTA (3), A. JAIN (3), I. ARIJS (4), G. VAN ASSCHE (5), M. FERRANTE (5), G. OPDENAKKER (6), S. VERMEIRE (5) / [1] KULeuven, [2] McGill University, Montreal, Canada, [3] Prometheus Laboratories Inc., San Diego, USA, [4] Jessa Hospital, Hasselt, [5] UZ Leuven, [6] Rega Institute for Medical Research

12:50 I 35 Beclomethasone dipropionaat is effective for microscopic colitis: results of an open label multicenter study (COLCO).

M. DE BRUYN (1), T. BESSISSOW (2), V. KONDRAGUNTA (3), A. JAIN (3), I. ARIJS (4), G. VAN ASSCHE (5), M. FERRANTE (5), G. OPDENAKKER (6), S. VERMEIRE (5) / [1] KULeuven, [2] McGill University, Mo T. DE CORTE (1), E. JANSSENS (1), K. THORREZ (3), A. D'HONDT (1), K. DEJAEGHER (4), F. D'HEYGERE (5), B. VAN BESIE (3), L. HARLET (1), H. PEETERS (6), W. VANMOERKERCKE (5), P. VAN HOOTEGEM (7), F. BAERT(1) / [1] AZ Delta, Roeselare, [2] [3] Jan Yperman Hospital, Ieper, [4] Sint-Jozefskliniek, Izegem, [5] AZ Groeninge, Kortrijk, [6] AZ Sint-Lucas, Gent, [7] AZ Sint-Lucas Brugge


12:55 Q & A



Belgian Week of
Gastroenterology
asbl / vzw

SAVE THE DATE

20 > 22 . 02 . 2019



www.bwge.be

HILTON ANTWERP
FEBRUARY 21-23 2018

TIFFANY / SHAH
(2nd Floor)



**1st BINAstoria
PROGRAM**

**SESSION 1
CHAIRS :**

An Sterckx, Valérie Wambacq, Marleen Goossens

09:00

Welcome and introduction
Liesbeth Moortgat, AZ Delta Roeselare

09:15

Patient empowerment :The key to treatment success in IBD
Prof. Pieter Hindryckx , UZ Gent

09:45

Colon cancer in IBD: Natural history and recommendations for screening and surveillance
Prof. Denis Franchimont, ULB Erasme Brussels

10:15

Therapeutic treatment with ustekinumab
Dr. Harald Peeters and Sophie Claeys, AZ St Lucas Gent

10:45

Coffee Break sponsored by AbbVie

Simultaneous
Translation
Sponsored by
Janssen-Cilag

**SESSION 2
CHAIRS :**

Patricia Geens, Frederika Van Dyck, Liesbeth Moortgat

11:15

Primary sclerosing cholangitis
Dr. Sofie Decock, AZ St Lucas Brugge

11:45

Dermatologic manifestations in IBD
Prof. Siegfried Segaeert, UZ Leuven

12:15

Clinical studies for dummies
Ils Van de Schoot, Imelda hospital Bonheiden & Sofie Himpe, AZ Groeninge Kortrijk

12:45

Closing Session
Valérie Wambacq, ULB Erasme Brussels

13:00

Lunch sponsored by Takeda

14:00 - 17:00

BSGIE Live transmission

With the Kind Support
of our Partners, BWGE
becomes possible!

Thank you !

PLATINIUM



GOLD

abbvie



BMS - Pfizer
Alliance



Bristol-Myers Squibb Belgium



SILVER

Boston
Scientific



Intercept

Lilly



OLYMPUS

PENTAX
MEDICAL

BRONZE

Acta Gastroenterologica

Analogic Benelux

Benetec

Biocodex

Boucart Medical

BTG Biocompatibles

Cook Medical

Dr Falk Pharma

Echosens

Erbe

Laborie

Lamepro

Mead Johnson

Mediquality

MPS - Vivactis

Mylan

Nestlé

Phacobel

Roche Software

RVC

Sandoz

Selinion

Shire

Tilman

Tramedico

What's up doc?

Will Pharma

ASSOCIATIONS

F.A.PA

CHAC

CHROHN FR

CHROHN NL

GBS - VBS

NASH EDUCATION PROGRAM